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A B S T R A C T
Background
Tobacco smoking in pregnancy causes serious health problems for the developing fetus and mother. When used by non-pregnant smokers,
pharmacotherapies (nicotine replacement therapy (NRT), bupropion, and varenicline) are eIective for increasing smoking cessation,
however their eIicacy and safety in pregnancy remains unknown. Electronic cigarettes (ECs) are becoming widely used, but their eIicacy
and safety when used for smoking cessation in pregnancy are also unknown.
Objectives
To determine the eIicacy and safety of smoking cessation pharmacotherapies and ECs used during pregnancy for smoking cessation in
later pregnancy and aCer childbirth, and to determine adherence to smoking cessation pharmacotherapies and ECs for smoking cessation
during pregnancy.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (20 May 2019), trial registers, and grey literature, and checked
references of retrieved studies.
Selection criteria
Randomised controlled trials (RCTs) conducted in pregnant women, comparing smoking cessation pharmacotherapy or EC use with either
placebo or no pharmacotherapy/EC control. We excluded quasi-randomised, cross-over, and within-participant designs, and RCTs with
additional intervention components not matched between trial arms.
Data collection and analysis
We followed standard Cochrane methods. The primary eIicacy outcome was smoking cessation in later pregnancy; safety was assessed
by 11 outcomes (principally birth outcomes) that indicated neonatal and infant well-being. We also collated data on adherence to trial
treatments. We calculated the risk ratio (RR) or mean diIerence (MD) and the 95% confidence intervals (CI) for each outcome for each
study, where possible. We grouped eligible studies according to the type of comparison. We carried out meta-analyses where appropriate.
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Main results
We included 11 trials that enrolled a total of 2412 pregnant women who smoked at enrolment, nine trials of NRT and two trials of bupropion
as adjuncts to behavioural support, with comparable behavioural support provided in the control arms. No trials investigated varenicline
or ECs. We assessed four trials as at low risk of bias overall. The overall certainty of the evidence was low across outcomes and comparisons
as assessed using GRADE, with reductions in confidence due to risk of bias, imprecision, and inconsistency.
Compared to placebo and non-placebo (behavioural support only) controls, there was low-certainty evidence that NRT increased the
likelihood of smoking abstinence in later pregnancy (RR 1.37, 95% CI 1.08 to 1.74; I2 = 34%, 9 studies, 2336 women). However, in subgroup
analysis by comparator type, there was a subgroup diIerence between placebo-controlled and non-placebo controlled RCTs (test for
subgroup diIerences P = 0.008). There was unclear evidence of an eIect in placebo-controlled RCTs (RR 1.21, 95% CI 0.95 to 1.55; I2 = 0%, 6
studies, 2063 women), whereas non-placebo-controlled trials showed clearer evidence of a benefit (RR 8.55, 95% CI 2.05 to 35.71; I2 = 0%,
3 studies, 273 women). An additional subgroup analysis in which studies were grouped by the type of NRT used found no diIerence in the
eIectiveness of NRT in those using patches or fast-acting NRT (test for subgroup diIerences P = 0.08).
There was no evidence of a diIerence between NRT and control groups in rates of miscarriage, stillbirth, premature birth, birthweight, low
birthweight, admissions to neonatal intensive care, caesarean section, congenital abnormalities, or neonatal death. In one study infants
born to women who had been randomised to NRT had higher rates of 'survival without developmental impairment' at two years of age
compared to the placebo group. Non-serious adverse eIects observed with NRT included headache, nausea, and local reactions (e.g. skin
irritation from patches or foul taste from gum), but data could not be pooled. Adherence to NRT treatment regimens was generally low.
We identified low-certainty evidence that there was no diIerence in smoking abstinence rates observed in later pregnancy in women using
bupropion when compared to placebo control (RR 0.74, 95% CI 0.21 to 2.64; I2 = 0%, 2 studies, 76 women). Evidence investigating the safety
outcomes of bupropion use was sparse, but the existing evidence showed no diIerence between the bupropion and control group.
Authors' conclusions
NRT used for smoking cessation in pregnancy may increase smoking cessation rates in late pregnancy. However, this evidence is of low
certainty, as the eIect was not evident when potentially biased, non-placebo-controlled RCTs were excluded from the analysis. Future
studies may therefore change this conclusion. We found no evidence that NRT has either positive or negative impacts on birth outcomes;
however, the evidence for some of these outcomes was also judged to be of low certainty due to imprecision and inconsistency. We found
no evidence that bupropion may be an eIective aid for smoking cessation during pregnancy, and there was little evidence evaluating its
safety in this population. Further research evidence on the eIicacy and safety of pharmacotherapy and EC use for smoking cessation in
pregnancy is needed, ideally from placebo-controlled RCTs that achieve higher adherence rates and that monitor infants' outcomes into
childhood. Future RCTs of NRT should investigate higher doses than those tested in the studies included in this review.
P L A I N   L A N G U A G E   S U M M A R Y
Drug treatments and electronic cigarettes for stopping smoking in pregnancy
What is the issue?
Smoking during pregnancy harms women and infants. However, many women who smoke struggle to stop whilst pregnant. Medication
for smoking cessation reduces the intensity of cravings, meaning that people trying to stop smoking are more likely to succeed in the long
term. Providing pregnant women who smoke with these treatments could help them to stop smoking and have a positive impact on both
their own health and the health of their infants.
Why is this important?
Medications commonly used to help people to stop smoking include nicotine replacement therapy (NRT), bupropion, and varenicline.
Electronic cigarettes containing nicotine are also used by some who smoke to help avoid smoking. However, the safety and eIectiveness
of smoking cessation drugs and electronic cigarettes in pregnant women is unknown. We searched for studies looking at how good these
aids were at helping pregnant women stop smoking and how safe they were when used during pregnancy.
What evidence did we find?
We searched for evidence on 20 May 2019 and identified 11 randomised studies (studies in which participants are assigned to one of two or
more treatment groups using a random method) that enrolled a total of 2412 women. Nine studies tested NRT used alongside counselling
to stop smoking, whilst the other two studies tested bupropion.
Low-quality evidence suggests that NRT combined with behavioural support might help women to stop smoking in later pregnancy more
than behavioural support alone. Medication trials oCen use placebos, that is tablets or patches that look like the drug but do not actually
include it, so that each comparison group has equal expectation of success and there is a fairer test of the benefits of the medicine itself.
When just the higher-quality, placebo-controlled trials were analysed, the evidence suggested that NRT was more eIective than placebo
NRT. There was no evidence that either nicotine patches or fast-acting NRT (such as gum or lozenge) was more eIective than the other.
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Low-quality evidence suggests that bupropion may be no more eIective than placebo in helping women quit smoking later in pregnancy.
We found no trials investigating other smoking cessation pharmacotherapies or electronic cigarettes.
There was insuIicient evidence to conclude whether NRT had either positive or negative impacts on rates of miscarriage, stillbirth, preterm
birth (less than 37 weeks), mean birthweight, low birthweight (less than 2500 g), admissions of babies to neonatal intensive care, or
newborn deaths. However, in one trial where infants were followed until two years of age, those infants born to women who had been
randomised to NRT were more likely to have healthy development. Similarly, it is unclear whether bupropion had a positive or negative
impact on birth outcomes.
Studies that looked at whether women used their stop smoking medications as instructed found that use was generally low, and the
majority of women used little of the NRT they were given.
What does this mean?
More research evidence is needed, in particular placebo-controlled trials that test higher doses of NRT, encourage women to use suIicient
medication, and follow infants into childhood. Furthermore, more studies are required investigating the eIect and safety of bupropion,
electronic cigarettes, and varenicline for giving up smoking during pregnancy.
Pharmacological interventions for promoting smoking cessation during pregnancy (Review)


























































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Nicotine replacement therapy compared to control for smoking cessation during pregnancy
Nicotine replacement therapy compared to control for smoking cessation during pregnancy
Patient or population: pregnant women who smoke
Setting: public hospitals and antenatal clinics (Australia, Canada, Denmark, France, the UK, the USA)
Intervention: nicotine replacement therapy
Comparison: placebo plus similar/matched behavioural support or similar/matched behavioural support only














smoking cessation at the lat-
est point in pregnancy (20
weeks' gestation or more)









Study populationMean birthweight (g)
3139 g 3 3239 g (3132 g to 3345 g)







Study populationMiscarriage and spontaneous
abortion
0 per 100 1 per 100 (0 to 2)





*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; NRT: nicotine replacement therapy; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.




















































































































































1Downgraded one level due to serious risk of bias: in the subgroup of studies at low or unclear risk of bias the eIect was no longer statistically significant, and there were significant
subgroup diIerences when comparing these studies to the three studies judged to be at high risk of bias (P = 0.008).
2Downgraded one level due to serious imprecision: there were only 253 events in total (300 to 400 recommended for dichotomous outcomes), and confidence intervals span both
minimal clinical benefit and considerable clinical benefit.
3Control risk based on observed birthweights in the control arms.
4Downgraded one level due to serious inconsistency: I2 = 70%, not explained by subgroup diIerences.
5Downgraded one level due to serious imprecision: confidence intervals encompass no diIerence as well as a clinically significant benefit.
6Downgraded two levels due to very serious imprecision: there were only 12 events in total (300 to 400 recommended for dichotomous outcomes), and confidence intervals
encompass both no diIerence and potential harm.
 
 
Summary of findings 2.   Bupropion compared to control for smoking cessation during pregnancy
Bupropion compared to control for smoking cessation during pregnancy
Patient or population: pregnant women who smoke
Setting: antenatal clinics (USA)
Intervention: bupropion
Comparison: placebo plus similar/matched behavioural support
Anticipated absolute effects* (95% CI)Outcomes










Study populationBiochemically validated smoking
cessation at the latest point in preg-









Study populationMean birthweight (g)
3090 g 2 3212 g (2991 g to 3434 g)







Study populationMiscarriage and spontaneous abor-
tion
n/a n/a
n/a n/a n/a No studies re-
ported this
outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; n/a: not applicable; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence




















































































































































Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
1Downgraded two levels due to very serious imprecision: very few events and participants, so very likely to be underpowered. Confidence intervals are wide and incorporate both
clinically significant benefit and clinically significant harm.
2Control risk based on observed birthweights in the control arms.
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B A C K G R O U N D
Description of the condition
Risks associated with smoking in pregnancy
Tobacco smoking during pregnancy is one of the most significant,
potentially preventable causes of a range of adverse pregnancy
outcomes, including placental abruption, miscarriage, stillbirth,
preterm birth (less than 37 weeks' gestation), and low birthweight
(less than 2500 g) (Hammoud 2005; Marufu 2015; Salihu 2007;
US DHHS 2004). Smoking causes intrauterine growth restriction,
probably through a reduction in the supply of oxygen and other
essential fetal nutrients (Crawford 2008), and is associated with
poorer fetal neurodevelopment (Herrmann 2008). Preterm birth is
the leading cause of neonatal mortality and morbidity (Hammoud
2005; Kramer 1987; Liu 2016), with up to half of all paediatric
neurodevelopmental problems ascribed to preterm birth (Bentley
2016; Green 2005). Low birthweight is a surrogate measure of
the harmful impact of tobacco smoking on fetal development,
and there is evidence of an association between low birthweight
and adult morbidities, including coronary heart disease and type
2 diabetes mellitus (Belbasis 2016; Gluckman 2008). Tobacco
smoking also has many long-term health impacts for women, and
is a major risk factor for six of the eight leading causes of death
globally (WHO 2019).
Epidemiology of smoking in pregnancy
Tobacco smoking is frequently associated with low socioeconomic
status and has been cited as one of the principal causes of health
inequality between rich and poor (Wanless 2004).
Overall, it is estimated that 29 of 174 countries have a prevalence
of smoking during pregnancy greater than 10%, and 12 countries
have a prevalence greater than 20% (Lange 2018). Ireland (38%),
Uruguay (30%), and Bulgaria (29%) are the three countries
estimated to have the highest prevalence of smoking during
pregnancy (Lange 2018). In high-income countries such as the USA,
Denmark, and Sweden, the prevalence of smoking in pregnancy
declined from between 20% and 35% in the 1980s to between 10%
and 20% in the 2000s (Al-Sahab 2010; Cnattingius 2004; Dixon 2009;
Giovino 2007; Tappin 2010; Tong 2009; US DHHS 2004), and to below
10% in 2010 (Lanting 2012). However, the decline has not been
consistent across all sectors of society, with lower rates of decline
in lower socioeconomic groups (Graham 2010; Lanting 2012;
Pickett 2009; US DHHS 2004). There are marked socioeconomic
diIerences between women who continue to smoke in pregnancy
and those who do not. Compared to women who do not smoke,
those who continue to smoke in pregnancy generally have lower
incomes, higher parity, lower levels of social support, and more
limited education; are younger; receive publicly funded or deficient
maternity care; are without a partner or with a partner who
smokes; and are more likely to feel criticised by society (Ebert 2007;
Frost 1994; Graham 1976; Graham 1996; Schneider 2008; Tappin
1996; US DHHS 2004). There is a significantly higher prevalence of
smoking in pregnancy in several indigenous and ethnic minority
groups, which is in accord with their social and material deprivation
(Chan 2001; Hunt 2003; Kaplan 1997; US DHHS 2004; Wiemann
1994). Despite the high prevalence, there is a paucity of evidence-
based literature on interventions to reduce antenatal smoking in
indigenous groups (Gilligan 2007). In some migrant groups, cultural
diIerences may cut across this social gradient. Women who are
migrants or refugees to the UK, Northern Europe, North America,
or Australia and who originate from South East Asia retain a
lower prevalence of smoking, despite major social disadvantage
(Bush 2003; Potter 1996; Small 2000). However, second-generation
migrant women are more likely to smoke during pregnancy (Troe
2008). In the USA, African-American, Hispanic, and Pacific Islander
women have a lower prevalence of smoking in pregnancy than
white women (Andreski 1995; US DHHS 2004; Wiemann 1994).
The global tobacco smoking epidemic is shiCing from high-
income countries to low- and middle-income ones, with predictions
that 80% of the 8 million annual tobacco-related deaths will
be occurring in low-middle income countries within 30 years
(Oncken 2010). Worldwide, the prevalence of tobacco smoking
and smokeless tobacco use amongst women is increasing, not
decreasing, and is expected to rise to 20% by 2025 (Oncken
2010; Richmond 2003; Samet 2001). The World Health Organization
(WHO) has identified this rise of tobacco use in young females
in low-income, high-population countries as one of the most
ominous developments of the tobacco epidemic (WHO 2019).
National rates of smoking in pregnancy appear to be associated
with economic development: for example, in Spain the prevalence
is estimated at 26%, whilst the prevalence in African Region is still
very low (Lange 2018). However, given the aggressive nature of
tobacco marketing, there is concern that prevalence of smoking in
pregnancy will increase with economic development (WHO 2019),
with subsequent health impacts on countries with already high
disease burdens and limited resources to provide health care, and
in particular neonatal care (Cnattingius 2004).
In addition to the socioeconomic factors associated with continued
smoking, there is a growing understanding of psychological
associations, especially mood disorders, stress, and childhood
trauma (Aveyard 2007; Blalock 2005; Blalock 2011; Crittenden
2007). Depressed women are up to four times more likely to
smoke during pregnancy than non-depressed women (Blalock
2005), but there is limited information available about the eIects of
smoking and interventions in pregnant women with psychological
symptoms, as these women are oCen excluded from trials (Blalock
2005). Two reviews in the general population, Stead 2013; Tsoi 2013,
and several trials of smoking cessation interventions conducted
in pregnant women report higher levels of stress and depression
amongst women who continue to smoke during pregnancy
(Aveyard 2007; Blalock 2005; Crittenden 2007).
A higher proportion of women stop smoking during pregnancy than
at other times in their lives. Up to 45% of women who smoke before
pregnancy 'spontaneously quit' or stop before their first antenatal
visit (Quinn 1991; The NHS Information Centre 2011; Woodby 1999);
this 'quit rate' is substantially higher than reported in the general
population (McBride 2003). 'Spontaneous quitters' usually smoke
less and are more likely to have temporarily stopped smoking
previously; to have a non-smoking partner; to have more support
and encouragement at home for quitting; to have stronger beliefs
about the dangers of smoking; and to be less seriously addicted
(Baric 1977; Ryan 1980). Consequently, women who are eligible
for smoking cessation assistance in pregnancy are likely to find it
more diIicult to quit than those in other populations. However,
only a third of women who stop smoking spontaneously remain
abstinent aCer one year (CDC 2002). McBride 2003 hypothesises
that pregnancy may be a 'teachable moment' at which women
perceive increased risk from smoking and become more motivated
to attempt smoking cessation. These factors highlight some of the
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major diIerences between the non-pregnant population included
in trials of pharmacotherapy for smoking cessation and pregnant
women who continue to smoke aCer they become pregnant
(Oncken 2009b).
Smoking cessation in pregnancy
In addition to acknowledged benefits for maternal health, stopping
smoking in pregnancy has positive impacts on infant outcomes.
Research studies show that smoking cessation interventions
delivered in pregnancy reduce the prevalence of infants born
at low birthweight, which is accompanied by substantial infant
morbidity and mortality (Chamberlain 2017). Similar findings
have been observed in women who stop smoking aCer receiving
standard antenatal care, suggesting that trial findings are probably
generalisable to all women who stop smoking in early pregnancy,
whether or not they participate in research studies (McCowan
2009).
Some non-pharmacological (psychosocial) interventions are
eIective in reducing the proportion of women who smoke during
pregnancy; the evidence for these can be obtained from an
associated review (Chamberlain 2017). For example, compared to
usual care (minimal information about smoking risks and advice to
quit or a less intensive intervention), smoking cessation counselling
was demonstrated to improve smoking abstinence rates in late
pregnancy (risk ratio (RR) 1.44, 95% confidence interval (CI) 1.19 to
1.73; I2 = 49%, 30 studies) (Chamberlain 2017). Financial incentives
have also shown evidence of eIectiveness, based on 10 trials of
2571 pregnant women (Notley 2019). However, all studies were
conducted in the USA or the UK, and incentives used in addition to
routine care in other countries may have diIerent eIects.
Description of the intervention
We evaluated the eIectiveness of any pharmacological
intervention used to support women to stop smoking in pregnancy,
including electronic cigarettes (ECs).
Nicotine replacement therapy (NRT), bupropion, and varenicline
are widely available on prescription for smoking cessation, and
NRT is also available as an over-the-counter medication. They
are licenced as first-line treatments for smoking cessation in the
USA and the European Union, and are widely recommended in
many national guidelines for use in the general population. ECs
are also freely available to buy in some countries, and many
people use them as an aid to smoking cessation (McNeill 2018). We
have therefore concentrated on these four treatments; however,
any pharmacological intervention used for smoking cessation was
eligible for inclusion in the review.
In previous Cochrane Reviews, NRT, bupropion, and varenicline
have all been found to improve the chances of quitting smoking
in non-pregnant adults who smoke (Cahill 2016; Hartmann-Boyce
2018; Hughes 2014). Another Cochrane Review found evidence from
two trials that ECs helped non-pregnant adults stop smoking in
the long term compared to placebo ECs; however, due to the small
number of trials and low event rates, confidence in the findings was
low (Hartmann-Boyce 2016). A more recent randomised trial found
that ECs were more eIective than NRT for smoking cessation in
non-pregnant adults who smoke (Hajek 2019).
The treatments are described as follows.
1. NRT: is available as patches in various dosages (absorbed slowly
through the skin) and in fast-acting forms, such as chewing gum,
lozenges, sublingual tablets, sprays, and inhalers (absorbed
through the oral or nasal mucosa).
2. Bupropion: this was developed as a non-tricyclic
antidepressant, but was licenced as a prescription-only smoking
cessation aid in the UK in 2000. The usual dose for smoking
cessation is 150 mg once a day for 3 days, increasing to 150 mg
twice a day, continued for 7 to 12 weeks. The quit attempt is
generally initiated a week aCer starting pharmacotherapy.
3. Varenicline: this is a selective nicotinic receptor partial agonist,
licenced as a prescription-only treatment for smoking cessation
in the USA in 2006, and in Europe in 2006/2007. The standard
regimen is 1 mg twice a day for 12 weeks, with the first week
titrated to reduce side eIects, and quit date set for the second
week of use.
4. ECs: these are devices that do not burn tobacco leaves;
instead, a nicotine-containing aerosol is released and inhaled
by the user (Cobb 2010). The awareness and use of ECs are
increasing (Filippidis 2017; Zhu 2017), and there is evidence that
some women are using ECs to quit smoking during pregnancy
(Oncken 2017). However, both the WHO and Centers for Disease
Control and Prevention advise that there is insuIicient evidence
to recommend e-cigarettes for smoking cessation in adults,
including pregnant women (US DHHS 2016; WHO 2019).
How the intervention might work
1. NRT: this aims to replace the nicotine inhaled through tobacco
smoking with nicotine in a medicinal form. In doing so,
the user avoids approximately 4000 toxins that are inhaled
with nicotine in tobacco smoke (Stedman 1968); medicinal
nicotine is therefore likely to be safer than tobacco smoke
nicotine. The nicotine provided through NRT should also reduce
motivation to smoke and the physiological and psychomotor
withdrawal symptoms oCen experienced during an attempt to
stop smoking, thereby increasing the likelihood of remaining
abstinent (West 2001).
2. Bupropion: this antidepressant has both dopaminergic
and noradrenergic actions, and appears to be a nicotinic
acetylcholinergic receptor antagonist (Fryer 1999; Slemmer
2000). Bupropion's mechanism of action for smoking cessation
remains uncertain, but it may block nicotine eIects, reduce
depression, or alleviate withdrawal symptoms (Cryan 2003;
Lerman 2002; West 2008).
3. Varenicline: this is an alpha 4 beta 2 nicotinic acetylcholine
receptor partial agonist. It attaches to the nicotinic acetylcholine
receptor and is believed to mimic the pleasurable dopaminergic
(dopamine-releasing) eIect of nicotine. Varenicline binds more
easily to receptors than nicotine, so that when abstinent
people who smoke use this drug, receptors become blocked
with varenicline. Should varenicline users choose to smoke,
varenicline prevents nicotine from attaching to receptors,
preventing any pleasurable eIects for the person smoking
(Coe 2005). Smoking whilst using varenicline is therefore less
enjoyable and attractive. Varenicline users also experience
fewer cravings or withdrawal symptoms and so are better able
to remain abstinent (Coe 2005).
4. ECs: similar to NRT, ECs deliver nicotine in order to reduce
withdrawal symptoms and motivation to smoke. ECs are
thought to address the behavioural as well as the biochemical
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aspects of smoking addiction (Barbeau 2013). ECs replace some
of the habitual gestures associated with cigarette smoking, such
as the hand-to-mouth actions, and this in combination with
nicotine delivery could help EC users remain abstinent during a
quit attempt (Polosa 2011).
One would expect these interventions to have the same
mechanisms of action in pregnant women as they do in non-
pregnant people who smoke. However, the metabolism of many
drugs, including nicotine, is increased in pregnancy, and any
medications that are metabolised more swiCly can become less
eIective at standard doses. Both nicotine and cotinine, the primary
metabolite of nicotine, are metabolised much more quickly in
pregnancy, where clearance is 60% and 140% greater, respectively
(Dempsey 2001). Consequently, NRT and ECs used by pregnant
women would be expected to generate lower blood concentrations
of nicotine, and these might not adequately substitute for nicotine
received from smoking. One might therefore expect NRT and ECs
to be less eIective for smoking cessation in pregnancy than when
used outside of pregnancy. The metabolism of bupropion and
varenicline is not known to be altered in pregnancy.
Safety
A caveat to the use of pharmaceutical treatments for smoking
cessation in pregnancy is that of potential fetal harm caused
by their use. There are insuIicient studies investigating the fetal
impacts of either bupropion or varenicline use in pregnancy to
draw any conclusions about the safety of using either of these
treatments. There are, however, more studies demonstrating the
eIects of nicotine on the fetus, and these suggest that nicotine is
a fetal toxin (Dempsey 2001). Also, nicotine crosses the placenta
and accumulates in the developing fetus (Maritz 2009; Rore 2008),
causing concerns about both short-term eIects on newborns,
Gaither 2009, and longer-term impacts on infants, Bruin 2010.
However, as tobacco smoke contains nicotine plus many other
toxins, and NRT delivers nicotine alone, there is a consensus
amongst experts that maternal use of NRT in pregnancy should
be safer for the fetus than continued smoking of burnt cigarettes
(Benowitz 2000), although there is currently insuIicient research
evidence to support this view.
Why it is important to do this review
Guidelines from many countries recommend that NRT be oIered
for smoking cessation in pregnancy to heavy smokers who have
been unable to quit smoking using behavioural or psychosocial
methods (CAN-ADAPTT 2011; NICE 2010; RACGP 2014; RANZCOG
2014). We have been unable to find any clinical guidelines that
recommend using bupropion, varenicline, or ECs in pregnancy.
These treatments are not recommended in pregnancy as there
is very limited evidence for their safety (Oncken 2017; Rore
2008), and their use could involve fetal exposure to potential
additional toxins that could be avoided. In most high-income
countries (e.g. Canada, the USA, Australia, New Zealand), guidelines
recommend that pregnant women be oIered intermittent NRT-
delivery formulations (e.g. gum, lozenges, spray - classified as
category C drugs in pregnancy), rather than continuous ones (e.g.
patches - classified as category D) (Bruin 2010). The theoretical
rationale for this is that the overall dose of nicotine delivered by
intermittent formulations may be lower than that delivered by
continuous ones (Oncken 2009b), and that the peaks in blood
nicotine concentrations are more extreme, mimicking the action
of smoking. However, some experts recommend patches, as the
lower peak nicotine levels associated with these may induce fewer
adverse eIects, such as throat irritation (Oncken 2009b; Rore 2008).
Consensus-based recommendations about using NRT for smoking
cessation in pregnancy are underpinned by a belief that medicinal
NRT is safer than smoking. (Benowitz 2000) However, to date,
individual trials have had inconsistent findings (Pollak 2007;
Wisborg 2000), and there is no conclusive evidence that NRT is
either eIective or safe in pregnancy (Coleman 2015). There are also
reports of low adherence to NRT regimens, which could reduce
eIicacy and suggests that the acceptability of NRT use in pregnancy
may be limited (Coleman 2011; Coleman 2012). Furthermore, it is
unclear whether eIicacy or safety is improved with intermittent
NRT administration (fast-acting NRT products) or with continuous
administration using nicotine patches.
Given that NRT appears to be widely accepted for cautious use
in pregnancy, a Cochrane Review investigating the eIicacy and
safety of this clinical practice and also the potential for other drugs
to be safely used was warranted. Additionally, although ECs are
not recognised or regulated as a smoking cessation treatment, as
they are widely available in some countries it is possible that they
may be used by pregnant women to quit smoking, and therefore
clear guidance is needed on this. An up-to-date, robust synthesis
of research evidence on the use of pharmacological treatments for
cessation in pregnancy will help advance clinical practice in an area
of substantial clinical need. This review updates an earlier version
of this review published in 2015 (Coleman 2015).
O B J E C T I V E S
To determine the eIicacy and safety of smoking cessation
pharmacotherapies and ECs used during pregnancy for smoking
cessation in later pregnancy and aCer childbirth, and to determine
adherence to smoking cessation pharmacotherapies and ECs for
smoking cessation during pregnancy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Parallel- or cluster-randomised controlled trials (RCTs) were eligible
for inclusion. Quasi-randomised, cross-over, and within-participant
designs were not eligible for inclusion due to the potential biases
inherent in these designs.
Types of participants
Women who were pregnant and who also smoked tobacco at study
baseline.
Types of interventions
Pharmacological treatments (including ECs) aimed at promoting
smoking cessation including, but not limited to, treatments that
have been proven eIective in non-pregnant adults (e.g. NRT
(Hartmann-Boyce 2018), bupropion (Hughes 2014), varenicline
(Cahill 2016), and ECs used to promote smoking cessation (Hajek
2019)).
Eligible comparators were placebo control or no smoking cessation
pharmacotherapy/EC.
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Trials could provide behavioural support to participants, however
the support provided had to be very similar (ideally identical)
across the active drug and comparator trial arms. Behavioural
support is eIective for smoking cessation in pregnancy
(Chamberlain 2017), and diIerences in its provision would be
expected to aIect cessation and birth outcomes, potentially
rendering findings diIicult to interpret.
Types of outcome measures
Primary outcomes
Self-reported abstinence from smoking at the latest time point
in pregnancy at which this was measured and, where available,
validated biochemically using measures such as exhaled carbon
monoxide, saliva cotinine, or, in those who are not smoking but
using nicotine (e.g. from NRT or ECs), anabasine. When validated
abstinence data were available, these were preferred to self-report.
Where this information was available, we also used prolonged or
continuous abstinence measures, timed from a quit date set in
early pregnancy and which allowed temporary lapses to smoking
as per the Russell Standard criteria for outcome measurement
in cessation studies (West 2005). However, point prevalence
abstinence measures were substituted for these as required.
Secondary outcomes
1. Abstinence from smoking aCer childbirth (with abstinence




c. Mean unadjusted birthweight
d. Low birthweight (less than 2500 g)
e. Preterm birth (less than 37 weeks' gestation)





k. Infant respiratory symptoms
l. Infant development
3. Pharmacotherapy/EC adherence
4. Non-serious adverse eIects (serious adverse event data
contributed to safety outcomes, as described above)
5. Any reported long-term eIects of smoking cessation
pharmacotherapies on safety
We did not carry out a specific literature search for outcomes 3
to 5, but, if reported, these data were extracted from the included
studies and described qualitatively.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Trials
Register by contacting their Information Specialist, who ran the
search on 20 May 2019.
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO) (Cumulative Index to
Nursing and Allied Health Literature);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals plus
monthly BioMed Central email alerts;
7. scoping searches of the US National Institutes of Health Ongoing
Trials Register ClinicalTrials.gov (clinicaltrials.gov/) and the
World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch/) for unpublished, planned,
and ongoing trial reports.
Based on the intervention described, each trial report is assigned
a number that corresponds to a specific Pregnancy and Childbirth
review topic (or topics), and is then added to the Register. The
Information Specialist searches the Register for each review using
this topic number rather than keywords. This results in a more
specific search set that has been fully accounted for in the relevant
review sections (Included, Excluded, Awaiting Classification, or
Ongoing).
Details of the search strategies for CENTRAL, MEDLINE, Embase,
and CINAHL; the list of handsearched journals and conference
proceedings; and the list of journals reviewed via the current
awareness service can be found in the ‘PCG Trials Register’ section
of the Cochrane Pregnancy and Childbirth Group's website.
Searching other resources
We checked relevant cited studies whilst reviewing the
trial reports identified by the electronic searches, as
well as reference lists from any directly relevant reviews
identified. We also searched the following trials registers
on 20 May 2019: US National Institutes of Health Ongoing
Trials Register ClinicalTrials.gov (clinicaltrials.gov/) and the
World Health Organization International Clinical Trials Registry
Platform (apps.who.int/trialsearch/), and OpenGrey, "System for
Information on Grey Literature in Europe” (www.opengrey.eu/).
We did not apply any language or date restrictions, and included
studies regardless of the publication type (e.g. conference abstract,
trial registry entry, journal article).
Data collection and analysis
For methods used in the previous version of this review, see
Coleman 2015.
For this update, the following methods were used to assess the 11
reports identified as a result of the updated search.
Selection of studies
This describes the identification of papers published since the
last version of this review and added to those included in earlier
versions (see Other published versions of this review). Two review
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authors (RC and TC) independently inspected the search results,
making separate lists of titles and abstracts that were potentially
suitable for inclusion. We then retrieved the full texts of reports
deemed potentially relevant, and two review authors (RC and
TC) assessed these for inclusion in the review. At both stages
disagreements were resolved by discussion without the need to
involve a third review author.
Data extraction and management
We designed a data extraction form based on that used by Lumley
2009, which two review authors (RC and TC) used to extract data
from eligible studies. Extracted data were compared, with any
discrepancies being resolved through discussion. RC entered data
into Review Manager 5 soCware (Review Manager 2014), double
checking this for accuracy.
When information regarding any of the above was unclear, we
contacted authors of the reports to provide further details.
We recorded the following information, where available, in the
Characteristics of included studies table.
1. Methods: study design.
2. Participants: number of participants, inclusion criteria, and any
relevant exclusion criteria.
3. Interventions: description of intervention and control
(treatment, dosage, regimen, behavioural support, duration of
intervention), information regarding dose matching if relevant.
4. Outcomes: primary outcomes, time points reported,
biochemical validation, and definitions of abstinence.
5. Notes: we recorded dates of the trial, trial funding, and
declarations of interest of trial authors where reported.
We created Additional tables for details of twin births and fetal loss
in pregnancy (Table 1) and for extracted adherence data (Table 2).
Assessment of risk of bias in included studies
RC and TC independently assessed risk of bias for all studies which
they had not authored (the one study led by TC was assessed by
another review author), using criteria adapted from those in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2019). Any disagreements were resolved by discussion with a third
review author (JLB).
We assessed the following 'Risk of bias' domains for all included
studies.
(1) Random sequence generation (checking for possible
selection bias)
We determined whether the method used to generate the
allocation sequence was suIiciently described to permit an
assessment of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random number
table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We determined the method used to conceal the allocation
sequence and whether intervention allocation could have been
foreseen in advance of or during recruitment, or changed aCer
assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth); or
• unclear risk of bias.  
(3) Blinding (checking for possible performance bias and
detection bias)
We determined the methods used, if any, to blind study participants
and personnel from knowledge of which intervention was received
by the participant. In the previous version of this review, we
categorised studies that used placebo as at low risk of bias and
those that used a behavioural control only as at high risk of
bias. Using this categorisation of bias, findings with respect to
eIicacy of NRT were diIerent for placebo (low risk of bias) and
non-placebo (high risk of bias) RCTs, so we have maintained the
same classification for this update. In the 'Risk of bias' table (see
Characteristics of included studies) we also note whether or not
participants, personnel, and outcome assessors were blinded to
outcome assessment and whether the abstinence outcome was
biochemically validated. We used cut points derived by expert
consensus: 8 parts per million where exhaled carbon monoxide was
used for validation and 10 ng/mL for saliva cotinine.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We determined for the primary outcome (i.e. smoking cessation)
the completeness of data including attrition and exclusions
from the analysis and whether an intention-to-treat analysis (i.e.
reporting trial arm cessation rates amongst all participants who
were originally randomised to that arm) was reported. We assessed
whether attrition and exclusions were reported, the numbers
included in the analysis at each stage (compared with the total
randomised participants), reasons for attrition or exclusion where
reported, and whether missing data were balanced across groups
or were related to outcomes.
(5) Selective reporting bias
We determined the possibility of selective outcome reporting bias
and assessed methods as:
• low risk of bias (where it was clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where a prespecified outcome is not reported
and there is evidence that this is due to lack of eIect or an eIect
deemed unfavourable); or
• unclear risk of bias (where not all of the study’s prespecified
outcomes have been reported; one or more reported primary
outcomes were not prespecified; outcomes of interest are
reported incompletely and so cannot be used; or the study
fails to include results of a key outcome that would have been
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expected to have been reported, however there is no clear
evidence that this is a source of bias).
(6) Other risk of bias
We considered whether there were any other additional potential
sources of bias in the study.
(7) Overall risk of bias
Where a study was judged to be at low risk for all of the above
domains, it was considered to be at overall low risk of bias; where
at least one judgement of high risk of bias was made, the study was
considered to be at overall high risk of bias; and where there was no
judgement of high risk, but at least one judgement of unclear risk,
the study was considered to be at overall unclear risk of bias.
Assessment of the certainty of the evidence using the GRADE
approach
We used the GRADE approach to assess the certainty of the body of
evidence relating to the following outcomes for each comparison
(NRT versus control; bupropion versus control) (Schünemann
2013), as recommended in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2019):
• smoking cessation at the latest point in pregnancy (primary
outcome);
• mean birthweight (safety outcome). We chose mean birthweight
because it can be used as a marker of multiple infant safety
outcomes;
• miscarriage and spontaneous abortion (safety outcome). We
chose this alongside mean birthweight because it is an
important safety outcome that would not be reflected in the
above mean birthweight outcome.
We used GRADEpro GDT to import data from Review Manager 5 in
order to create 'Summary of findings' tables (Summary of findings
for the main comparison; Summary of findings 2) (GRADEpro GDT;
Review Manager 2014). A summary of the intervention eIect and a
measure of certainty for the above outcomes was produced using
the GRADE approach. The GRADE approach uses five considerations
(study limitations, consistency of eIect, imprecision, indirectness,
and publication bias) to assess the certainty of the body of evidence
for each outcome. The evidence can be downgraded from 'high
certainty' by one level for serious (or two levels for very serious)
limitations, depending on each of these considerations.
Measures of treatment e9ect
Dichotomous data
For dichotomous data (all outcomes except mean birthweight),
including smoking cessation, we have presented results as
summary risk ratios (RR) with 95% confidence intervals (CI). A RR
> 1 for the smoking cessation outcomes indicates benefit of the
intervention. For undesirable outcomes, such as preterm births, RR
< 1 indicates benefit of the intervention.
Continuous data
For mean birthweight (continuous data), we have presented the
mean diIerence (MD) between control and intervention groups
with 95% CI.
Unit of analysis issues
Multiple pregnancies
The unit of analysis for smoking cessation was the trial
participant, regardless of whether she had a singleton or multiple
pregnancy. For all other outcomes, analyses were conducted
amongst singleton births only; this approach was undertaken
because adverse pregnancy events/outcomes, adverse infant birth
outcomes, and poorer infant development are strongly associated
with multiple pregnancy. Hence, analysing multiple and singleton
pregnancies together for these outcomes could render review
findings diIicult to interpret. Outcome data from multiple births
were insuIicient for these to be analysed separately.
Cluster-randomised trials
This study design was eligible for inclusion, however no cluster-
randomised trials were identified. If in future updates such trials
are identified, we will include them in the analyses along with
individually randomised trials. We will adjust their sample sizes
or standard errors using the methods described in Sections 16.3.4
and 16.3.6 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2019), employing an estimate of the
intracluster correlation co-eIicient (ICC) derived from the trial
(if possible), from a similar trial, or from a study of a similar
population. If we use ICCs from other sources, we will report
this and conduct sensitivity analyses to investigate the eIect of
variation in the ICC. If we identify both cluster-randomised trials
and individually randomised trials, we will synthesise the relevant
information. We will consider it reasonable to combine the results
from both if there is little heterogeneity between the study designs,
and the interaction between the eIect of intervention and the
choice of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the eIects of the
randomisation unit.
Dealing with missing data
For the primary smoking abstinence outcome, we assumed any
participants lost to follow-up were still smoking or had relapsed
to smoking, using the Russell Standard criteria (West 2005). At all
outcome points, participants whose smoking status was unknown
were assumed to be smoking.
We used the following denominators for other outcomes.
• For the pre-birth outcomes miscarriage/spontaneous abortion
and stillbirth, the denominator used was the number of
women randomised with viable singleton pregnancies at the
time of randomisation. Where terminations occurred aCer
randomisation, terminated fetuses were excluded from the
denominator if terminations were performed on a presumed
viable fetus for non-medical reasons. Similarly, pregnancies that
were documented as non-viable at the point of randomisation
were also excluded from this denominator (e.g. missed
abortion). Where terminations were undertaken for medical
reasons and were judged incompatible with life, these cases
were included in denominators and also within numerators;
they were counted as miscarriages if performed before 24
weeks, and as stillbirths if conducted aCer this time point.
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• For mean unadjusted birthweight (i.e. the only birth outcome
measured on a continuous scale), the denominator used was the
number of singleton births for which this outcome was recorded.
• For dichotomous birth outcomes (e.g. low birthweight, preterm
birth, neonatal intensive care admissions, and neonatal death),
the denominator used was the number of live births from
singleton pregnancies.
• For infant outcomes, the number of live births was used.
For selected secondary outcomes and where appropriate and
feasible, we conducted sensitivity analyses to investigate the
impact of missing data on pooled treatment eIect estimates.
For all outcomes, we carried out analyses, to the greatest degree
possible, on an intention-to-treat basis (caveats outlined above);
we attempted to include all participants randomised to each group
in analyses, and all participants were analysed in the group to
which they had been allocated regardless of whether or not they
received the allocated intervention.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis visually
by inspecting the overlap of 95% CIs for the individual studies
on the forest plots. We quantified heterogeneity using the I2
statistic (Higgins 2019). We regarded heterogeneity as substantial
and hence worthy of further investigation (see Subgroup analysis
and investigation of heterogeneity) if the I2 was greater than 50%,
and considerable and incompatible with presenting as pooled
analyses if greater than 75%. Where it was not possible to perform
a meta-analysis due to considerable levels of heterogeneity (I2
> 75%), we summarised the data for each trial and conducted
subgroup analyses (see Subgroup analysis and investigation of
heterogeneity) to explore the reasons for the heterogeneity.
Assessment of reporting biases
As there were fewer than 10 studies in all meta-analyses, we did
not draw funnel plots to assess the potential for reporting bias. If in
future updates of this review there are 10 or more studies, we will
investigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually if asymmetry is
suggested by a visual assessment, and we will perform exploratory
analyses to investigate it.
Data synthesis
We carried out statistical analysis using Review Manager 5
soCware (Review Manager 2014). Following the standard methods
of the Cochrane Tobacco Addiction Group for pharmacological
interventions, we elected to use a fixed-eIect model for meta-
analyses of smoking abstinence data. For meta-analyses of safety
and adverse events data, we used random-eIects models, as
eIects are likely to vary across populations due to significant
diIerences in baseline risk. Where it was not possible to perform
a meta-analysis due to considerable levels of heterogeneity (I2 >
75%), we have summarised the data for each trial. If in future
updates of the review more than 10 studies are included in a
meta-analysis, we may consider performing meta-regression to
further explore reasons for heterogeneity or to analyse adherence
data. A caveat to using this method for adherence data is that
there is currently no standard method for reporting adherence;
however, for meta-regression to be undertaken, studies must report
adherence data similarly.
Subgroup analysis and investigation of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the I2 statistic. We performed an exploration of heterogeneity
for primary and secondary outcomes where the I2 was greater
than 50%. Where substantial heterogeneity was detected between
studies, an overall pooled result was presented; however, readers
are advised to use caution in interpreting results due to the
presence of heterogeneity.
For smoking cessation outcomes, we explored reasons for
heterogeneity between the studies using subgroup analyses based
on the following groups.
1. Placebo-controlled versus non-placebo-controlled RCTs
2. Studies using diIerent types of NRT, both alone and in
combination (i.e. fast-acting NRT and nicotine patch)
3. Low-dose NRT (< 10 mg/24 hours) versus high-dose NRT (> 10
mg/24 hours)
For secondary outcomes, where the I2 was greater than 50%
(indicating substantial heterogeneity), we also performed these
subgroup analyses as an exploration of heterogeneity; however,
they were not conducted routinely for all secondary outcomes.
We assessed diIerences between subgroups statistically using
subgroup interaction tests, and have presented the P values from
these tests.
Sensitivity analysis
We planned two sensitivity analyses using smoking cessation
outcomes, depending on the availability of data.
1. Excluding studies rated at high risk of bias overall.
2. Excluding any studies that reported substantially lower
treatment adherence than others. As there is no consensus
on what constitutes good or acceptable adherence to NRT
in pregnancy, we anticipated defining 'low adherence' aCer
consideration of adherence data reported within the included
studies.
We were unable to carry out these analyses for the current review
(explanations follow in the Results section); they will be undertaken
in future review updates, data permitting.
R E S U L T S
Description of studies
Results of the search
We carried out an updated search of the Cochrane Pregnancy and
Childbirth Group’s Trials Register on 20 May 2019 and identified
14 trial reports for potential inclusion. We also deemed a further
study, which had recently been published and so was not identified
by searches, as potentially relevant (Oncken 2019). We identified
a total of 15 trial reports for title and abstract screening, of which
eight studies were clearly not RCTs and were excluded.
We obtained the full text of the seven remaining records for
screening. We excluded one article (Gould 2019), assessed four
articles as ongoing studies (see below), and included two articles in
this update (Nanovskaya 2017; Oncken 2019). Details of the flow of
studies for this update are recorded in a PRISMA diagram in Figure
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1. Nine trials included in previous versions of this review are also
included in this update (Berlin 2014; Coleman 2012; El-Mohandes
2013; Hotham 2006; Kapur 2001; Oncken 2008; Pollak 2007; Stotts
2015; Wisborg 2000).
 
Figure 1.   Study flow diagram for most recent update.
 
This updated review therefore includes a total of 11 trials (34
reports). It contains data from two additional trials published since
the previous version (Nanovskaya 2017; Oncken 2019), and involves
a total of 2412 pregnant women who smoked at study baseline. We
added two newly identified reports of Coleman 2012 and two new
reports of Berlin 2014. Details of each included study can be found
in the Characteristics of included studies table.
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Included studies
Interventions
Nine studies investigated the eIicacy of diIerent forms of NRT
(Berlin 2014; Coleman 2012; El-Mohandes 2013; Hotham 2006;
Kapur 2001; Oncken 2008; Oncken 2019; Pollak 2007; Wisborg
2000); two studies investigated bupropion (Nanovskaya 2017;
Stotts 2015); and no trials investigated other smoking cessation
pharmacotherapies or ECs.
Nicotine replacement therapy studies
All of the included studies investigated the eIicacy of NRT
provided with behavioural support and compared this with either
behavioural support alone or support plus a placebo, therefore
studies measured the eIect of NRT provided as an adjunct to
behavioural support. Seven papers, Berlin 2014; Coleman 2012;
Cooper 2014; Kapur 2001; Oncken 2008; Oncken 2019; Wisborg
2000, described six placebo-controlled RCTs (Berlin 2014; Coleman
2012; Kapur 2001; Oncken 2008; Oncken 2019; Wisborg 2000). Three
trials compared NRT plus behavioural support with behavioural
support alone (El-Mohandes 2013; Hotham 2006; Pollak 2007);
participants in these studies could not be blinded to treatment.
Two studies used fast-acting NRT, one using nicotine gum, Oncken
2008, and the other nicotine inhalers, Oncken 2019; six trials used
nicotine patches (Berlin 2014; Coleman 2012; El-Mohandes 2013;
Hotham 2006; Kapur 2001; Wisborg 2000); and one oIered a choice
of NRT formulations: approximately two-thirds of participants
chose patches, whilst the remainder elected to use gum and
lozenges (Pollak 2007).
Oncken 2008 used 2 mg nicotine gum, and Oncken 2019 used 4
mg nicotine inhalers. Four studies used 15 mg/16-hour nicotine
patches (Coleman 2012; Hotham 2006; Pollak 2007; Wisborg 2000);
one of these used a higher nicotine dose (21 mg/24 hours
removed at night) for participants who reported smoking more
than 15 daily cigarettes (Pollak 2007). Two studies attempted to
match nicotine doses prescribed with either saliva, Berlin 2014,
or urinary cotinine levels, El-Mohandes 2013, obtained at earlier
appointments. Depending on cotinine levels, women in one study
were treated with combinations of 10 mg and 15 mg 16-hour
patches (Berlin 2014), and in the other study with 21 mg, 14 mg, or 7
mg 24-hour patches, with instructions to remove these at night (El-
Mohandes 2013). One trial advised women to use trial treatments
from randomisation until childbirth, irrespective of whether or
not they had relapsed to smoking (Berlin 2014), and another trial
encouraged continued use of treatment for six weeks as long as the
woman was actively trying to quit smoking (Oncken 2019). Other
trials advised women to stop using NRT if they restarted smoking
and had a defined period for use of NRT.
Bupropion studies
Two studies were placebo-controlled RCTs investigating bupropion
(Nanovskaya 2017; Stotts 2015). One study experienced
recruitment challenges and randomised only 11 women (Stotts
2015). Nanovskaya 2017 initially aimed to randomise 100 women,
however aCer two years the sample size calculation was adjusted
as the original calculation was overpowered for craving scores
and there was diIiculty enrolling participants. The revised sample
calculation aimed for 30 participants per treatment group, and 65
were recruited overall. Participants in the Stotts 2015 study were
prescribed 150 mg bupropion sustained-release for the first three
days of the study, which was then doubled to 300 mg per day (150
mg twice a day) for the remainder of the eight weeks of the trial,
whereas Nanovskaya 2017 prescribed participants 300 mg per day
(150 mg twice a day) bupropion sustained-release for a duration of
12 weeks.
Setting
Studies were conducted in the USA (n = 6) (El-Mohandes 2013;
Nanovskaya 2017; Oncken 2008; Oncken 2019; Pollak 2007; Stotts
2015), Australia (n = 1) (Hotham 2006), Canada (n = 1) (Kapur 2001),
Denmark (n = 1) (Wisborg 2000), France (n =1) (Berlin 2014), and
England (n = 1) (Coleman 2012). All trials were conducted in public
hospitals or antenatal clinics.
Outcomes
The small bupropion trial (n = 11) ascertained smoking cessation
at nine weeks aCer enrolment (mean gestation at enrolment = 16
weeks) (Stotts 2015), and in a small NRT trial (n = 40), smoking
cessation was ascertained between 20 and 28 weeks' gestation
(Kapur 2001); however, in all other studies this was ascertained
at 32 weeks or later.  In all of the included studies, biological
samples were obtained from participants, and aCer any required
clarification from the authors we determined that all used such
samples to validate reported cessation at the primary endpoint:
four studies used exhaled carbon monoxide (El-Mohandes 2013;
Hotham 2006; Oncken 2008; Oncken 2019); four saliva cotinine
(Berlin 2014; Pollak 2007; Stotts 2015; Wisborg 2000); and one
used both exhaled carbon monoxide and saliva cotinine (Coleman
2012). One study used both exhaled carbon monoxide and urinary
cotinine (Nanovskaya 2017), whilst only one study reported both
thiocyanate and cotinine concentrations (cut points are listed
in the Characteristics of included studies section) (Kapur 2001).
For two studies, cut points were obtained from the trial authors
(Pollak 2007; Wisborg 2000), and we obtained further data on
biochemical validation from the authors of a trial that used
a higher-than-standard cut point for saliva cotinine (26 ng/mL)
(Wisborg 2000).  This revealed that the cotinine assay used had
a lower limit of 20 ng/mL, which was also above the currently
accepted cut point of 10 ng/mL, so some women who smoke may
have been wrongly categorised as abstinent in this study. 
The periods of abstinence from smoking that participants were
required to demonstrate varied across studies. For smoking
outcomes measured at delivery, three studies reported both
seven-day point prevalence abstinence from smoking and a
measure of continuous abstinence simultaneously (Berlin 2014;
Coleman 2012; Pollak 2007); however, definitions varied. One
study, Coleman 2012, permitted a small number of temporary
lapses to smoking as recommended by the Russell Standard
criteria for outcome measurement in smoking cessation studies
(West 2005). The remaining two studies did not permit temporary
lapses and defined continuous abstinence as seven-day point
prevalence abstinence recorded on three, Pollak 2007, or up to
seven occasions (Berlin 2014). Six studies reported only seven-
day point prevalence abstinence (Nanovskaya 2017; Oncken 2008;
Oncken 2019; Pollak 2007; Stotts 2015; Wisborg 2000), and three
reported point prevalence abstinence for an unstated period (El-
Mohandes 2013; Hotham 2006; Kapur 2001). Four studies reported
seven-day point prevalence abstinence data at time points aCer
childbirth: Wisborg 2000 provided data at three and 12 months
postnatally; Coleman 2012 at six, 12, and 24 months; Oncken 2008
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at six to 12 weeks (biochemically validated data); and Pollak 2007
at three months. Additionally, Coleman 2012 reported continuous
abstinence between a quit date and each time point, allowing for
temporary lapses too.
Infant and fetal safety outcomes were reported in eight studies
(Berlin 2014; Coleman 2012; El-Mohandes 2013; Nanovskaya 2017;
Oncken 2008; Oncken 2019; Pollak 2007; Wisborg 2000). All eight
of these studies reported mean birthweight and mean gestation
age at delivery, and all but one reported the incidences of low
birthweight births (defined as below 2500 g) (Nanovskaya 2017).
Six of these studies reported rates of preterm birth defined as
born before 37 weeks' gestation (Berlin 2014; Coleman 2012;
Oncken 2008; Oncken 2019; Pollak 2007; Wisborg 2000), with one
reporting preterm birth defined as born before 34 weeks' gestation
(Nanovskaya 2017). Six studies reported rates of miscarriage/
spontaneous abortion and stillbirth (Berlin 2014; Coleman 2012;
Oncken 2008; Oncken 2019; Pollak 2007; Wisborg 2000), and five
trials also reported infants’ rates of special care admission and
neonatal death (Berlin 2014; Coleman 2012; Nanovskaya 2017;
Oncken 2008; Pollak 2007). Three trials reported data on maternal
hypertension in pregnancy or measured arterial blood pressure at
each visit (Berlin 2014; Coleman 2012; Nanovskaya 2017), three
trials reported rates of congenital malformation (Berlin 2014;
Coleman 2012; Oncken 2019); and two of these three trials reported
rates of caesarean section (Berlin 2014; Coleman 2012). Details
of twin-birth pregnancies in studies where these occurred, and
for those trials that reported birth outcomes, details of fetal
loss in pregnancy and of subsequent live births within singleton
pregnancies, are provided in Table 1. Two trials reported single and
multiple pregnancy data together, but authors supplied data for
singleton pregnancies separately (Berlin 2014; Pollak 2007).
With regard to the pre-birth fetal outcomes of miscarriage/
spontaneous abortion and stillbirth, Oncken 2008 reported that,
within singleton pregnancies, three control group participants
had terminations that were performed for social reasons
(presumed healthy fetus), so these fetuses were removed from the
denominator for control group analyses (control group n = 91). Also,
Pollak 2007 reported one fetal death prior to randomisation that
was documented by ultrasound scanning (i.e. a 'missed abortion')
in the NRT group, so this fetus was removed from the denominator
for the NRT group (NRT group n = 121). Coleman 2012 reported
one termination and one fetal death prior to randomisation in
women allocated to NRT, so these two cases were removed from
the NRT group denominator (NRT group n = 515). Berlin 2014
reported one termination in each trial group, both of which
were conducted for fetal abnormalities that were assessed as not
being compatible with survival at birth. Consequently, as these
terminations were undertaken at 25 (placebo group) and 32 weeks,
they have been counted as stillbirths in the analysis and remained
in the denominator as well.
Two studies reported self-reported maternal smoking at 12 months
aCer childbirth (Coleman 2012; Wisborg 2000); Coleman 2012
additionally reported infants' "survival without developmental
impairment" and respiratory symptoms at two years of age
and self-reported maternal smoking at six and 24 months aCer
childbirth.
Ongoing studies
There were five ongoing studies in the previous version of the
review. Two of these were completed with results published and
are now included studies (Nanovskaya 2017; Oncken 2019). We
excluded one study that stopped due to recruitment problems,
NCT00744913, and another that was not an RCT (NCT00888979).
The one remaining trial is a trial of bupropion and is still recruiting
(NCT02188459). We identified four ongoing studies for this update.
There is uncertainty regarding the publication of results for
one of these trials (NCT01875172), which was retrospectively
registered in 2013, but is listed as completed in January 2004.
We attempted to contact the author for clarification but were
unable to do so. One study appears to oIer NRT as part of
a multicomponent intervention (ACTRN12618000972224), which
would not be included in this review; however, we will wait for
further information to become available before making a decision
to exclude. The remaining ongoing studies include an NRT trial,
IRCT20181209041904N1, and an EC trial (ISRCTN62025374). For
further details, see Characteristics of ongoing studies.
Excluded studies
We excluded one trial following full-text screening in this update
(Gould 2019). This was a pilot cluster-randomised step-wedge
trial, where NRT was part of a multimodal intervention that
provided educational resources to health providers at aboriginal
medical services. We judged that due to the study design and
the multimodal intervention strategy, it was not possible to
identify the independent eIect of NRT on smoking cessation from
this study. Details and reasons for exclusion are shown in the
Characteristics of excluded studies table, alongside the two trials
previously categorised as ongoing described above (NCT00744913;
NCT00888979), and three other previously excluded studies (Eades
2012; Hegaard 2003; Oncken 2009a).
Risk of bias in included studies
We judged four of the 11 included studies to be at low overall risk
of bias (Berlin 2014; Coleman 2012; Oncken 2008; Wisborg 2000),
three as at high risk of bias (El-Mohandes 2013; Hotham 2006; Pollak
2007), and the remainder unclear risk of bias (Figure 2; Figure 3).
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Figure 2.   Methodological bias graph: review authors' judgements about each methodological bias item presented
as percentages across all included studies.
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Figure 3.   Methodological bias summary: review authors' judgements about each methodological bias item for each
included study.
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Allocation
Computer-generated random number sequences were used to
generate randomisation in most studies. Two studies used urn
randomisation methods and were judged to be at low risk of bias
for random sequence generation, but were unclear for allocation
concealment due to insuIicient detail (Nanovskaya 2017; Oncken
2019). One study used sealed envelopes aCer random numbers
had been generated, but it was not clear if these were opaque and
sequentially numbered (Hotham 2006), and another study gave no
details of how randomisation was operationalised (Stotts 2015); we
therefore judged both studies to be unclear at unclear risk of bias
for allocation, whilst the others were rated as satisfactory (low risk
of bias).
Blinding
We judged studies that had no placebo control to be at a high risk
of bias, which was the principal diIerence between studies that
was likely to cause bias. Eight trials were placebo-controlled RCTs
(Berlin 2014; Coleman 2012; Kapur 2001; Nanovskaya 2017; Oncken
2008; Oncken 2019; Stotts 2015; Wisborg 2000), and three studies
compared behavioural support alone with NRT and behavioural
support (El-Mohandes 2013; Hotham 2006; Pollak 2007).
In smoking cessation studies, bias can also occur at outcome
ascertainment if trial participants report that they have stopped
smoking when actually they have not. Generally, it is perceived
that the broadly negative social view of smoking can result
in self-perceived pressure on participants in smoking cessation
studies to be seen as having successfully stopped smoking, and
this may result in false reporting of abstinence from smoking at
follow-up. Trialists attempt to minimise this bias (detection bias)
through use of biochemical validation of self-reported smoking
status data which is collected for trial outcomes. As all included
trials biochemically validated self-reported smoking outcomes,
this is not a major issue for this review. However, one included
study used a cut point for saliva cotinine (26 ng/mL) that was
substantially higher than the currently accepted level (10 ng/mL)
and, additionally, used an assay with a lower limit of measurement
of 20 ng/mL (i.e. samples in the 0 to 20 ng/mL range were reported
as 20 ng/mL) (Wisborg 2000). This means that some of those few
participants who falsely reported themselves as not smoking in this
study might have had their false reports of abstinence validated
as true (i.e. some participants who were actually smoking might
not have had this detected by the validation process). Of course,
no validation process is perfect, and, using any cut point, some
false reports of cessation would be accepted to be true, but with a
known high cut point as in Wisborg 2000, this would be expected to
occur more frequently. However, the use of biochemical validation
in this study would still be expected to detect heavier smoking
in those who made false reports of abstinence, so validated data
from this study were still used in preference to self-report data. One
bupropion study also used a relatively high cut point (20 ng/mL), so
similar issues are also relevant to that trial (Stotts 2015).
Incomplete outcome data
We judged all studies to be at low risk of bias for smoking abstinence
outcomes; all studies carried out an intention-to-treat analysis,
so that those participants who could not be contacted at follow-
up were assumed to have returned to smoking. It should be
noted that this assumption is conservative and is the standard
approach taken when assessing the eIicacy of smoking cessation
interventions. Follow-up for birth outcomes was generally high
with one exception: the treatment group allocation for seven
women who experienced miscarriage aCer being randomised
within one study could not be ascertained (Wisborg 2000); as this
was not the primary outcome, we assessed this trial as at low risk
of attrition bias.
Selective reporting
We judged five studies as at unclear risk of reporting bias. Hotham
2006 and Stotts 2015 both collected data on a number of outcomes
that were not reported in the trial manuscript; however, it is
unclear whether this was a source of bias. We requested birthweight
information from Hotham 2006 for our meta-analysis but were
unable to obtain it. El-Mohandes 2013 informed us that within
their trial, some data on secondary smoking cessation outcomes
were collected, but this information was not reported in the trial
manuscript; however, primary outcomes were reported. Kapur
2001 did not report any birth outcomes. Nanovskaya 2017 reported
measuring low birthweight as an outcome but these data are not
presented. Furthermore, this study defined preterm births as any
births occurring before 34 weeks' gestation, whereas the current
accepted definition is less than 37 weeks' gestation. This means
that any births occurring between 34 and 37 weeks' gestation
would not be classified as preterm. We judged the remaining six
studies to be at low risk of reporting bias.
Other potential sources of bias
We identified an unanticipated potential source of bias in one
study (El-Mohandes 2013): two participants were screened and
randomised on two separate occasions, with each pregnancy
counted as a discrete study participation, and both women
included in the trial analysis twice. We considered this as
potentially introducing bias into what was a relatively small study,
and so judged this study as at high risk of bias.
E9ects of interventions
See: Summary of findings for the main comparison Nicotine
replacement therapy compared to control for smoking cessation
during pregnancy; Summary of findings 2 Bupropion compared to
control for smoking cessation during pregnancy
Data were not identified for all pre-specified outcomes. Where data
were available this is summarised below. Where outcomes are not
discussed they were not reported.
Primary outcomes (e9icacy)
Nicotine replacement therapy
In a pooled analysis of nine included studies and 2336 participants,
we found evidence that the use of NRT, as an adjunct to behavioural
support, may result in a clinically significant improvement in
smoking cessation rates in pregnancy relative to control (risk ratio
(RR) 1.37, 95% confidence interval (CI 1.08) to 1.74; I2 = 34%;
Analysis 1.1).
We carried out a subgroup analysis splitting the studies by
comparator type - placebo or no placebo- and found evidence of
a subgroup diIerence (P = 0.008; Analysis 1.1). In the subgroup
that compared active NRT with placebo, heterogeneity between
studies was substantially reduced (I2 = 0%), however the CIs
incorporated the potential for both no eIect and a benefit of NRT
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for smoking cessation (RR 1.21, 95% CI 0.95 to 1.55; 6 studies,
2063 women; Analysis 1.1), whereas the estimate derived from non-
placebo-controlled trials indicated only benefit (RR 8.55, 95% CI
2.05 to 35.71; I2 = 0%, 3 studies; 273 women), but was limited
by substantial imprecision. When analysing the data split into
fast-acting and nicotine patch subgroups, the test for subgroup
diIerences provided no evidence that the eIect of NRT diIered by
type (P = 0.08; Analysis 1.2).
We planned to carry out a sensitivity analysis removing all studies
judged to be at high risk of bias. The six studies that did not have
a high risk of bias for any domain were the same six studies in the
placebo-controlled trials subgroup. This analysis and resulting 95%
CI found evidence of potentially no clear eIect of NRT, as well as
the potential for benefit, therefore its interpretation does diIer very
slightly from that of the overall pooled analysis (Analysis 1.1). We
were unable to conduct the planned sensitivity analysis relating to
adherence to treatment as trials reported adherence so diIerently
that it was not possible to categorise one or more trials as having
substantially worse or better treatment adherence than others.
We investigated the impact of NRT as an adjunct to behavioural
support on cessation at time points aCer childbirth by pooling data
from studies that provided postnatal follow-up data on smoking
behaviour. In a pooled analysis of studies that reported non-
validated seven-day point prevalence smoking abstinence up to
six months aCer childbirth (predominantly at or around three
months), there was no clear evidence that NRT compared to
placebo or no placebo control was eIective for smoking cessation,
as CIs incorporated both potential benefit and harm of the
intervention (RR 1.22, 95% CI 0.84 to 1.78; I2 = 0%, 3 studies, 625
women; Analysis 1.3). There was no statistical subgroup diIerence
when comparing studies that were placebo controlled to the one
study that was not (P = 0.59). Similarly, the pooled estimate for non-
validated seven-day point prevalence smoking abstinence when
comparing NRT to placebo at one year aCer childbirth resulted in
CIs that incorporated both a small potentially negative eIect of
NRT, as well as a potentially positive eIect at this time point (RR
1.35, 95% CI 0.97 to 1.88; I2 = 5%, 2 studies, 1296 women; Analysis
1.4).
The one study that monitored continuous cessation from a quit
date set in pregnancy to postnatal time points alongside seven-
day point prevalence abstinence data collected at the same time
points reported higher point prevalence than continuous cessation
rates at each time point, and rates of continuous cessation until two
years aCer childbirth were low (2.9% in the NRT group versus 1.7%
in the placebo group, adjusted P = 0.12) (Coleman 2012).
Bupropion
In a pooled analysis of the two bupropion studies, we found no clear
evidence for an eIect of bupropion on smoking cessation during
later pregnancy (RR 0.74, 95% CI 0.21 to 2.64; I2 = 0%, 2 studies, 76
women; Analysis 2.1). However, there was substantial imprecision,
with the CIs incorporating both potential benefit and harm, likely
due to the small sample size. As neither study was judged to be at
high risk of bias, the sensitivity analysis removing studies at high
risk of bias was not relevant.
Secondary safety outcomes
Nicotine replacement therapy
Two study papers reported birth outcomes from single- and
multiple-birth infants together (Berlin 2014; Pollak 2007); the
authors kindly provided data on birth outcomes within singleton
pregnancies only. Details of twin births and fetal loss in pregnancy
are provided in Table 1.
There was no evidence of a diIerence in risk of miscarriage/
spontaneous abortion between the NRT and control group, and CIs
incorporated the possibility of both potential benefit and harm of
the intervention (RR 1.60, 95% CI 0.53 to 4.83; I2 = 0%, 5 studies,
1916 women; Analysis 1.5). However, despite contacting the study
authors, we could not determine the treatment allocation for
seven miscarriages from one study, which is not included in this
comparison (Wisborg 2000). If we assume that all miscarriages from
this study occurred in either the NRT or the control group (i.e. the
extremes of how these could actually be distributed), this results
in the following eIect estimates: all assumed in the NRT group:
RR 2.15, 95% CI 0.77 to 6.02; all assumed in the control group: RR
1.06, 95% CI 0.38 to 2.97. This has no eIect on the interpretation
of the results. Similarly, there was no evidence of a clear diIerence
between the numbers of stillbirths in the NRT and control groups
(RR 1.24, 95% CI 0.54 to 2.84; I2 = 0%, 4 studies, 1777 women;
Analysis 1.6).
The pooled estimate for birthweight was higher for the NRT group
than for the control group, but the CIs incorporated a small
decrease in birthweight as well as a more substantial increase
(mean diIerence (MD) 99.73 g, 95% CI −6.65 to 206.10; I2 = 70%,
7 studies, 2202 women; Analysis 1.7). Heterogeneity was high and
on the borderline for presenting pooled estimates; the result for
this comparison must therefore be interpreted with caution. The
reasons for this heterogeneity are unclear; it is not easily explained
by study design as one large placebo-controlled RCT, Coleman
2012, and a smaller non-placebo-controlled one, Pollak 2007, both
reported non-significantly lower birthweight in NRT group infants,
in contrast to other studies. There was a lower incidence of low
birthweight births in women in the NRT group, but again this was
not significant and was found in the context of much heterogeneity,
so caution is again warranted (RR 0.69, 95% CI 0.39 to 1.20; I2 = 69%,
7 studies, 2171 women; Analysis 1.8). The pattern of heterogeneity
was once again diIicult to understand: the same two studies
reported non-significantly higher rates of low-birthweight infants in
the NRT arm (Coleman 2012; Pollak 2007).
Analyses of rates of preterm births (RR 0.81, 95% CI 0.59 to 1.11;
I2 = 21%, 7 studies, 2182 women; Analysis 1.9), neonatal intensive
care unit admissions (RR 0.90, 95% CI 0.64 to 1.27; I2 = 0%, 4 studies,
1756 women; Analysis 1.10), and neonatal deaths (RR 0.66, 95%
CI 0.17 to 2.62; I2 = 0%, 4 studies, 1746 women; Analysis 1.11)
all resulted in CIs spanning one, incorporating the potential for
both benefit and harm. We also meta-analysed rates of congenital
anomalies and of caesarean birth (2 studies (Berlin 2014; Coleman
2012), 1401 women; Analysis 1.12 and Analysis 1.13, respectively).
In both cases the CIs suggested no clear evidence for a benefit or
harm of NRT (congenital anomaly: RR 0.73, 95% CI 0.36 to 1.48, I2 =
0%; caesarean section: RR 1.18, 95% CI 0.83 to 1.69, I2 = 46%). The
three studies that provided data on blood pressure (BP) reported
these in diIerent formats: Coleman 2012 reported that 24 (4.6%) in
the NRT group compared to 25 (4.7%) in placebo were noted to have
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hypertension in pregnancy (i.e. BP of greater than 140/90 mmHg)
on at least two occasions (no statistical comparison presented).
Berlin 2014 reported significantly higher median diastolic BP in
the NRT group (median BP = 70, interquartile range (IQR) = 60 to
80 mmHg) compared to placebo (median BP = 62, IQR = 60 to 80
mmHg) (P = 0.02). Berlin 2014 also reported an interaction between
treatment group and time (i.e. during pregnancy) for increases in
diastolic BP, though absolute increases in BP were small.
Coleman 2012 and Berlin 2014 also reported the distribution of
other birth outcomes between NRT and placebo groups such as
Apgar score at five minutes aCer birth, cord arterial blood pH,
intraventricular haemorrhage, neonatal convulsions, necrotising
enterocolitis, mechanical ventilation of infant, assisted vaginal
delivery, and maternal death; no statistically significant diIerences
were noted.
Coleman 2012 was the only included study that reported infant
outcomes aCer the neonatal period. Using a composite, self-
report outcome based on the Ages and Stages Questionnaire,
3rd edition (ASQ-3) instrument (Squires 2009), significantly better
infant developmental outcomes were observed in infants born to
women who had been randomised to NRT compared to those
in the placebo group. The odds ratio (OR) for infants reaching
two years of age 'without developmental impairment' (i.e. normal
development) was 1.40 (95% CI 1.05 to 1.86). However, there was
no diIerence in parental reports of infants' respiratory symptoms;
the OR for reporting of any respiratory problem in the NRT group
was 1.32 (95% CI 0.97 to 1.74).
Bupropion
In the bupropion trials, the pooled estimate for birthweight was
higher for the bupropion group than for the control group, but the
CIs incorporated evidence for both benefit and harm (MD 122.64 g,
95% CI −98.82 to 344.10; I2 = 0%, 2 studies, 68 women; Analysis 2.2).
Both bupropion studies also found no significant diIerence in mean
length of infants between trial groups (Nanovskaya 2017; Stotts
2015). In the one bupropion study that measured maternal blood
pressure (Nanovskaya 2017), there was no diIerence between the
bupropion and placebo groups in systolic (P = 0.46) and diastolic
blood pressure (P = 0.40) at the end of pregnancy.
Adherence and adverse e9ects
Nicotine replacement therapy
Where adherence was reported, this was generally low, as the
majority of participants in all studies did not use complete
courses of the NRT oIered; adherence data reported in trials are
summarised in Table 2. Berlin 2014 diIered from other studies in
that transdermal patches were oIered to women between their
quit dates and delivery. Much higher self-reported adherence rates
were noted in this study; however, it is diIicult to reconcile these
with reported rates of intervention discontinuation, and direct
comparison with other studies was not possible.
Only a narrative reporting of non-serious adverse eIect data
was possible. Six NRT trials reported non-serious adverse eIects
(Berlin 2014; Coleman 2012; Hotham 2006; Oncken 2008; Oncken
2019; Wisborg 2000). One trial reported their frequency within
women using NRT, noting that five (25%) women in the NRT group
experienced minor symptoms, and two women stopped using
patches aCer unpleasant eIects (Hotham 2006); however, non-
serious adverse eIects were not monitored in the control group,
so this figure is diIicult to interpret. Oncken 2008 reported that at
least 10% of participants experienced headache, dizziness, fatigue,
heartburn, nausea or vomiting, with 14 (15%) in the NRT and
12 (12%) in the control groups discontinuing treatment due to
adverse eIects. Wisborg 2000 noted that 11 women stated that
adverse eIects (e.g. skin irritations and headache) made them
discontinue patches, but did not report treatment allocations; this
trial also reported that five women experienced palpitations and
two nausea. Coleman 2012 noted 535 non-serious adverse events
reported by 521 NRT group participants and 450 reported by 529
placebo group participants. Berlin 2014 reported a range of non-
serious adverse events, noting that more non-gynaecological ones
occurred in the NRT group, but this was principally due to skin
reactions. In this study, 11% of participants in the NRT group
suIered a skin reaction at the patch site compared with 4% in the
placebo group. Oncken 2019 reported a significantly higher number
of adverse eIects in women using the nicotine inhaler (11%) than
the placebo inhaler (0%) (P = 0.008). These adverse events included
throat irritation, cough, and nausea. Furthermore, two women in
this study were discontinued from the nicotine inhaler group due
to repeated elevations in cotinine concentrations exceeding more
than 40% of their baseline cotinine concentration.
Bupropion
Both bupropion trials reported non-serious adverse eIects
(Nanovskaya 2017; Stotts 2015). Stotts 2015 reported that two
women suIered from vomiting in the bupropion group. Other
adverse eIects in the bupropion group included dry mouth, loss
of appetite, and agitation. In the placebo group, one woman
experienced agitation, and two reported nausea. None of these
women decided to discontinue the medication. Nanovskaya 2017
noted that women in both groups reported known adverse
eIects such as headache (29% bupropion, 11% placebo),
diIiculty sleeping (25% bupropion, 7% placebo), runny nose
(17% bupropion, 7% placebo), dry mouth (37.5% bupropion, 14%
placebo), and anxiety (33% bupropion, 18% placebo). However,
there was no statistical diIerences between groups.
D I S C U S S I O N
Summary of main results
Overall there is low-certainty evidence that NRT used alongside
behavioural support by pregnant women for smoking cessation
may increase smoking abstinence in late pregnancy (Summary
of findings for the main comparison). Caution is required when
interpreting this pooled estimate, as subgroup analyses revealed
potentially diIerent treatment eIects when comparing NRT to
placebo-controlled versus non-placebo-controlled studies. These
findings may be due to unexplained biases potentially within the
less robust, non-placebo-controlled trials. The actual eIicacy of
NRT used for smoking cessation in pregnancy is uncertain and may
be lower than the pooled summary estimate (Analysis 1.1). Further
subgroup analysis found no evidence that the eIect of NRT on
abstinence is moderated by the type of NRT used, that is patches
versus fast-acting NRT, and there was no consistent evidence of NRT
having either a positive or negative impact on birth outcomes.
We identified only two small bupropion trials, which provided
no clear evidence that bupropion improved smoking cessation
outcomes later in pregnancy. Similarly, we found no evidence that
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bupropion has any impact on birth outcomes. Due to the low
certainty and scarcity of the evidence, future research is likely to
change some of these conclusions.
We identified no eligible trials of varenicline or ECs for inclusion in
the review.
Overall completeness and applicability of evidence
All of the included studies were conducted in high-income
countries, with only one study specifically recruiting women from
ethnic minority backgrounds. These findings may therefore not be
applicable to low-middle-income countries if smoking patterns of
women or beliefs about using medication in pregnancy diIer, and
more evidence is needed from these populations.
An exclusion criterion for this review was unmatched additional
intervention components in the intervention or comparator arms.
As a result the only diIerence between trial arms was the provision
of pharmacotherapy (NRT or bupropion). This means that we can
be confident that we have isolated the independent eIects of the
interventions of interest to our review question.
It has been mandatory since July 2005 for clinical trials to be
recorded on a trials register. In this update we searched trials
registers from inception, therefore we are confident that we have
identified all reported ongoing trials.
The findings reported in this review are based on currently
accepted, evidence-based, biochemical verification cut points for
determining abstinence from smoking (SRNT 2002), rather than
ones that might have been acceptable in the past, enhancing the
validity of our findings.
Certainty of the evidence
The included trials had varied 'Risk of bias' ratings, as discussed
in the Risk of bias in included studies section. We assessed four
of the 11 included studies to be at low risk of bias, three at
high risk of bias, and the remainder at unclear risk of bias. We
judged the principal diIerence in studies' propensity to bias to
be due to the use/non-use of placebo controls. The reduction
in heterogeneity observed aCer dividing trials according to this
criterion seemed to validate this judgement. Trials that were judged
to be at an unclear risk of bias lacked information regarding
allocation concealment or did not report prespecified outcomes.
It is possible, but relatively unlikely, that the lack of information
regarding allocation concealment indicates bias.
We assessed the certainty of the evidence using the GRADE
approach. Our GRADE assessment of pooled data indicated that
the evidence for the smoking cessation outcome in NRT trials was
of low certainty (Summary of findings for the main comparison),
meaning that the true eIect might be markedly diIerent from
the estimated eIect. The current evidence was downgraded twice,
once due to risk of bias: in the subgroup of studies at low or
unclear risk of bias the eIect was no longer statistically significant,
and there were significant subgroup diIerences when comparing
these studies to the three studies judged to be at high risk of
bias. We downgraded the evidence further due to imprecision,
as there were few events, and confidence intervals spanned
both minimal clinical benefit and considerable clinical benefit.
We assessed the evidence for the safety outcomes in NRT trials,
mean birthweight and miscarriage, to be of low certainty. The
mean birthweight outcome was downgraded due to inconsistency
where heterogeneity was high and not explained by subgroup
diIerences, and was further downgraded due to imprecision, as
the confidence intervals encompassed no diIerence as well as
a clinically significant benefit. The miscarriage and spontaneous
abortion outcome was downgraded two levels to low certainty
due to imprecision, as there were too few events, and confidence
intervals encompassed both no diIerence and potential harm.
Our GRADE assessment indicated that the evidence for the smoking
cessation and mean birthweight outcomes in bupropion trials was
of low certainty (Summary of findings 2), meaning that the true
eIects might be markedly diIerent from the estimated eIects. We
downgraded the evidence in both cases twice for imprecision due
to the small number of events.
The downgrading of the evidence for all outcomes due to
imprecision suggests that further research will be beneficial in
increasing the reliability and precision of eIect estimates and the
certainty we are able to place in them.
Potential biases in the review process
We performed the search for studies in this area using the Cochrane
Pregnancy and Childbirth Group’s Trials Register. It is unlikely that
studies that have been conducted have been missed, however
it is possible that unpublished studies, or ongoing studies not
registered in clinical trial registries, could be missing. Should we
identify any such studies, we will include them in future updates
of the review. Secondly, we were unable to produce a funnel
plot as there were too few studies, and it is possible there was
publication bias. In future updates where there are suIicient
trials we will be able to assess publication bias more rigorously.
Unfortunately, we were unsuccessful in contacting the author for
one bupropion trial, where the trial record states that it was
completed in 2004 (NCT01875172). This could have had a significant
impact on the bupropion results in this review as it states that it
enrolled 135 participants, which is larger than both trials included
in this review. However, the certainty of the evidence would still
likely be downgraded for imprecision. Finally, we aimed to reduce
bias wherever possible by having at least two review authors
independently conduct study selection, data extraction, and 'Risk
of bias' assessment.
Agreements and disagreements with other studies or
reviews
This review explicitly assesses the eIicacy and safety of
pharmacological therapies used for smoking cessation in
pregnancy. Some trials of smoking cessation in pregnancy test
NRT as part of multimodal intervention strategies, and these are
included in an associated review (Chamberlain 2017). However,
this review was concerned with the eIicacy and safety of
pharmacological therapies when used for smoking cessation in
pregnancy, and examines the independent safety and eIicacy of
pharmacological interventions.
We have been unable to identify any other systematic reviews
that investigate the eIicacy of smoking cessation medications in
pregnancy since the previous version of this review was published
(Coleman 2015). A systematic review of trials conducted in non-
pregnant women has shown that NRT is eIective outside of
pregnancy (Hartmann-Boyce 2018). The reasons why NRT may not
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be as eIective in pregnancy are not known; however, variations
in adherence to NRT or nicotine metabolism compared to the
general population may play a part. Women in trials included
in the current review made relatively little use of oIered NRT. If
this low adherence explains the diIerence in findings between
this and the 'non-pregnancy' NRT review (Hartmann-Boyce 2018),
then understanding the phenomenon of low adherence could be
important. Lack of eIicacy could also be explained by the increased
metabolism of nicotine in pregnancy (Dempsey 2001). This may
result in NRT generating lower blood nicotine concentration in
pregnancy, and this reduced nicotine substitution could, in turn,
increase women's experience of withdrawal symptoms, causing
them to stop NRT early. A recent systematic review found that
pregnant women using NRT were exposed to significantly lower
concentrations of nicotine compared to those who continued to
smoke tobacco (Hickson 2019). Furthermore, a secondary analysis
of a trial included in our review found that pregnant women
who both smoke and use nicotine patches had similar cotinine
concentrations, smoke less, and exhale less carbon monoxide,
therefore they are likely to be exposed to fewer tobacco smoke
toxins (Claire 2019a). An increased metabolism of nicotine during
pregnancy results in lower exposure, and coupled with the
likelihood that nicotine is unlikely to be responsible for the majority
of fetal harms caused by tobacco smoke, it is likely that NRT is safer
for the fetus than smoking (Kumar 2019). Logically, if in trials to
date, increased metabolism underpinned women's low adherence
to NRT, higher doses of NRT could be needed for this to be eIective
in pregnancy.
We were unable to identify any other systematic reviews that
investigated the eIicacy of smoking cessation medications in
pregnancy, and we did not identify any RCTs investigating
varenicline for smoking cessation. However, a recent systematic
review and meta-analysis assessed the safety of bupropion and
varenicline in pregnancy (Turner 2018). This review included
cohort, case-control studies, and case reports as well as the two
bupropion RCTs included in this review. The authors of Turner
2018 were unable to find any evidence that either bupropion or
varenicline was harmful in pregnancy, but neither were they able
to identify any strong evidence that they were safe to use in
pregnancy.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
• The evidence suggests that nicotine replacement therapy (NRT)
may be eIective for smoking cessation in pregnancy, however
there is uncertainty surrounding this evidence. It is also unclear
whether NRT aIects the risk of adverse pregnancy and infant
outcomes, but there is no evidence that it is harmful. One study
suggests that NRT improves child development outcomes at two
years.
• There is insuIicient evidence on either the eIectiveness or
safety of bupropion, varenicline, or e-cigarettes in pregnancy to
guide clinical practice.
Implications for research
• There is a strong case for further trials to examine the
eIectiveness and safety of NRT against placebo. NRT leads to
lower blood nicotine concentrations than when smoking and
is eIective in the general population (Hartmann-Boyce 2018),
however there are also reasons why it may be less eIective
for pregnant women than for the general population, and the
evidence in pregnant women is uncertain.
• As adherence to NRT in pregnant women is low, further research
should seek to understand why this is and improve it and use
an appropriate behavioural strategy to enhance adherence in
future trials of NRT.
• In the general population, there is evidence that 25 mg/16-
hour patches are more eIective than 15 mg/16-hour patches
(Lindson 2019); most studies in this review used 15 mg patches.
Consequently, trials are needed in pregnant women using
either higher-dose nicotine patches or combination of patch
plus rapid-acting forms of NRT, which are also more eIective
(Lindson 2019).
• Given that NRT may be eIective, and there is some evidence for
the eIectiveness of nicotine-delivering e-cigarettes to support
smoking cessation in the general population (Hartmann-Boyce
2016), trials of e-cigarettes to support smoking cessation in
pregnancy would be valuable because e-cigarettes are more
popular than NRT.
• Trials of bupropion and varenicline for smoking cessation in
pregnancy may be justified providing the preclinical data do
not raise substantial safety concerns equivalent to the risk of
continued smoking in pregnancy.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Double-blind, placebo-controlled, parallel-group RCT
Participants 476 pregnant women aged ≥ 18 years, between 9 and 20 weeks' gestation who smoked at least 5 daily
cigarettes and scored at least 5 on a scale measuring motivation for quitting smoking (range 0 to 10)
Interventions Intervention and control differed only in the provision of active or visually identical placebo transder-
mal patches. The intervention patch delivered nicotine as nicotine replacement therapy over a 16-hour
period. Both 10 mg and 15 mg patches were used, and women's doses ranged from 10 mg to 30 mg per
day. A saliva sample was collected at the woman's first trial visit/contact with the research team. Be-
tween this and a second visit/contact, which occurred 2 weeks later, women were instructed to either
stop smoking or to reduce this to less than 5 daily cigarettes. Women who managed to reduce or stop
smoking in this way were, at their second visit, randomised to either placebo or active patch in a 1:1 ra-
tio. The nicotine dose used for women's first prescription of NRT (made at this 2nd trial visit) was based
on their saliva cotinine level obtained from the sample given at visit 1 with the aim being to attempt
100% substitution of nicotine obtained from smoking for that obtained via patches.
Women were instructed to use NRT from their quit date until delivery. Smoking and using patches was
not encouraged (this is described as a "safety concern"). However, if women did have a temporary
lapse to smoking, they were allowed to remain on NRT afterwards. Both groups received counselling on
how to use patches.
Outcomes There were 2 primary outcomes, 1 maternal and 1 relating to infants: complete, continuous abstinence
from smoking since the quit date and infant birthweight. A positive abstinence outcome was record-
ed where women self-reported 7 days abstinence from smoking at each study visit, and this was con-
firmed by an exhaled CO reading of 8 ppm or less. There were up to 7 study visits with the final visit in-
tended for 1 month prior to delivery; no lapses to smoking were permitted.
Notes The cessation outcome used was more stringent than in many studies; often some allowance for tem-
porary lapses to smoking is permitted, and many studies assess smoking status as a smaller number of
time points in pregnancy.
Dates of study: October 2007 to January 2013
Funding sources: "This study was funded by the Ministry of Health, France (grant No MA05 00150) and
co-sponsored by Assistance publique-Hôpitaux de Paris (P060604).The Ministry of Health and Assis-
tance publique-Hôpitaux de Paris had no role in the design and conduct of the study; the collection,
conduct, analysis, and interpretation of the data; or the preparation, review, or approval of the manu-
script." Gunnar Gustavsson and McNeil-Johnson & Johnson provided the nicotine and placebo patches
free of charge.
Declarations of interest: "All authors have completed the ICMJE uniform disclosure form at www.icm-
je.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that: none
had support of any kind for the submitted work; IB has served as a paid consultant for Pfizer, Novartis,
and Ethypharm in the past three years; none of the authors’ spouses, partners, or children has financial
relationships that may be relevant to the submitted work; and none of the authors has non-financial in-
terests that may be relevant to the submitted work."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A computer-generated randomisation list (allocation ratio 1:1) in blocks of 4
was prepared and kept double-blinded. 60 randomisation numbers were es-
tablished by centre. In case of more than 60 randomisations by centre, the
next randomisation list of 60 was added. The randomisation list by centre
was incorporated into the electronic case report form, and the randomisation
Berlin 2014 
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Low risk A statistician at the clinical research centre of the Assistance publique-Hôpi-
taux de Paris, who was fully independent of the trial, prepared the random,
computer-generated allocation sequence. The randomisation code was kept
in a sealed envelope in a safe. A copy of the randomisation code was kept sep-
arately in case of a serious adverse event necessitating exposure of a partic-
ipant’s group assignment. Investigators, members of the co-ordination cen-
tre, hospital pharmacists, and the study statistician were kept blinded until the
code was opened before witnesses on 19 February 2013.
Blinding (performance
bias and detection bias) 
Women and clinical staI
Low risk All study staI (investigators, pharmacists, members of the co-ordination cen-
tre and of the drug safety monitoring board, laboratory staI, statistician) were
double-blinded to treatment allocation. Placebo patches were identical (vi-
sually) to active ones. Determination of saliva cotinine levels was carried out
blinded, and investigators were not aware of the results.





Low risk There are similar rates of attendance for all trial visits, but no data are present-
ed on attendance at individual trial visits. However, for smoking outcomes all
women who could not be contacted are assumed to be still smoking, so the
potentially low follow-up rates do not affect this. Follow-up rates for birth out-
comes are high (e.g. only 3 women had no delivery data).
Selective reporting (re-
porting bias)
Low risk All prespecified outcomes appear to have been reported.
Overall assessment of bias
risk




Methods Double-blind, placebo-controlled RCT – stratified by trial centre only
Participants Pregnant women (n = 1050) who agreed to set a quit date, were 16 to 50 years of age, were at 12 to 24
weeks of gestation, smoked 10 or more cigarettes daily before pregnancy, currently smoked 5 or more
cigarettes daily, and had an exhaled CO concentration of at least 8 ppm
Interventions Intervention and control conditions differed only in the provision of transdermal patches; the interven-
tion group received active patches and the control group received placebo patches. Research midwives
were trained to provide behavioural support according to national standards, with the use of a manu-
al that included guidance from a British expert trainer of smoking-cessation professionals and behav-
ioural approaches from the Smoking Cessation or Reduction in Pregnancy Treatment trials that were
believed to be relevant to British people who smoke. At enrolment, research midwives provided behav-
ioural support lasting up to 1 h, and participants agreed to a quit date within the following 2 weeks; fol-
low-up was timed from the quit date. Subsequently, participants were randomly assigned to receive a
4-week supply of transdermal patches for NRT (at a dose of 15 mg per 16 h) or visually identical place-
bos, which were started on the quit date (all study treatment was purchased at market rates from Unit-
ed Pharmaceuticals). 1 month after the quit date, women who were not smoking, as validated by an ex-
haled CO concentration of less than 8 ppm, were issued another 4-week supply of patches. 
In addition to behavioural support at enrolment, research midwives provided 3 sessions of behavioural
support by telephone to participants: 1 session on the quit date, 1 session 3 days afterward, and 1 ses-
sion at 4 weeks. The women who collected a 2nd month’s supply of nicotine-replacement or placebo
patches also received face-to-face support from the research midwife at the time of collection. Women
Coleman 2012 
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were offered additional support from local National Health Service smoking cessation services and
were encouraged to ask for support from the research midwives or smoking cessation service staI;
support was provided according to the manual.
Outcomes Prolonged smoking cessation between a quit date soon after enrolment and delivery, validated by both
exhaled CO monitoring and saliva cotinine estimation. Cut points: exhaled CO, smoking was defined as
> 7 ppm; saliva cotinine, smoking defined as > 9 ng/dL. Birth outcomes including Apgar score at 5 min
after birth, cord arterial blood pH, intraventricular haemorrhage, neonatal convulsions, congenital ab-
normalities, necrotising enterocolitis, mechanical ventilation of infant, assisted vaginal delivery, ma-
ternal death, and caesarean section.
For infants: survival to 2 years of age without developmental impairment, reported respiratory symp-
toms. Maternal: self-reported abstinence from smoking for at least 7 days reported at 6, 12, and 24
months after childbirth, prolonged abstinence from smoking since a quit date set in pregnancy and un-
til 24-month follow-up (defined as having validate abstinence at delivery followed by reported absti-
nence at all outcome points listed above).
Notes Dates of study: May 2007 to February 2010
Funding sources: "Supported by a grant from the NIHR Health Technology Assessment Programme
(06/07/01)"
Declarations of interest: "No potential conflict of interest relevant to this article was reported."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated sequence, in random permuted blocks of randomly vary-
ing size and with stratification by recruiting site
Allocation concealment
(selection bias)
Low risk Allocation and dispensing of treatment/placebo packages by external clini-
cal trials unit, with all study staI and participants unaware of study allocation.
“Identically packaged study patches were dispensed, and all participants and
study personnel were unaware of the study assignments”
Blinding (performance
bias and detection bias) 
Women and clinical staI
Low risk It was clear from study text that participants and clinicians were adequately
blinded.
Although the report does not state that the outcome assessor was adequate-
ly blinded, this was confirmed in communication with the Chief Investigator,
who stated that the clinicians acted as outcome assessors and were complete-
ly blinded.
Biochemical validation of smoking cessation conducted at follow-up points




Low risk 1 participant excluded postrandomisation due to accidentally being enrolled
twice (control group); all other participants were included in intention-to-treat
analysis.
Intervention: 36 were excluded (24 lost to follow-up, 3 withdrew consent, 9
had fetal or infant death).
Control: 33 were excluded (22 lost to follow-up, 7 withdrew consent, 4 had fe-
tal or infant death).
Also, groups appeared to be balanced at follow-up, with 60% follow-up rates
for smoking outcomes and much higher rates for infant outcomes.
Coleman 2012  (Continued)
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Selective reporting (re-
porting bias)
Low risk Very detailed report of all outcomes and adverse outcomes
Overall assessment of bias
risk




Methods Non-placebo, parallel-design RCT
Participants 52 English-speaking pregnant women who smoked and were residents of Washington, DC in the USA, of
ethnic minority backgrounds, aged at least 18 years, and less than 30 weeks' gestation. Women needed
to express a desire to quit and have an expired-air CO reading of 8 ppm or less and a salivary cotinine of
20 ng/mL or less (NB: ClinicalTrials.gov website says 30 ng/mL or less) or a urinary cotinine of 100 ng/
mL or less.
Interventions 1:1 ratio randomisation, stratified by site and initial salivary cotinine levels to either 1) cognitive behav-
ioural therapy (CBT) and NRT transdermal patches or 2) CBT alone.
NRT: a 10-week course of 24-hour patches was offered, with initial dosing varying with baseline salivary
cotinine measurements. Women with levels of ≥ 100 ng/mL were issued 21 mg patches for 2 weeks, 14
mg patches for 4 weeks, and finally 7 mg patches for 4 weeks. Women with levels of ≥ 20 ng/mL and
≤ 100 ng/mL were issued 14 mg patches for 6 weeks and 7 mg patches for 4 weeks. The first batch of
patches was issued at the 2nd study visit at which salivary cotinine levels were available.
Participants were given clear verbal and written instructions on patch use. They were advised never to
smoke whilst using the patch, to remove the patch before going to sleep, and not to use other NRT con-
currently.
CBT: this was the same for both groups.
Outcomes Smoking cessation outcome: during the study participants made 6 visits to the study team in the ante-
natal period. At visit 2 (V2), trial interventions were initiated, and at each of visits V3 to V6 (the last be-
fore childbirth), women were asked if they had smoked since their previous clinic visit (e.g. at V3, they
were asked if they had smoked since V2). Participants who reported smoking cessation had this vali-
dated using exhaled CO, with abstinence viewed as confirmed by a reading of < 8 ppm. The trial man-
uscript reports point prevalence of abstinence from smoking at each time point, and data from V6 are
used in analyses. All data were validated (self-report not available), but the period of abstinence that
was validated is unclear and varied with the interval between clinic visits.
Secondary outcomes reported in the trial manuscript: premature birth (i.e. at < 37 weeks' gestation);
gestational age at birth; mean birthweight and low birthweight < 2500 g.
The following outcomes were also collected, as clarified by the authors: ability to not smoke for 24 h or
more; longest number of days that the woman was able to go without even a puI of smoking; frequen-
cy of smoking at least puI during the last 7 days; number of cigarettes smoked each day; number of
cigarettes smoked during the past 24 h; and frequency of use of other forms of tobacco.
Notes TItle of paper states that it was conducted in "African-American smokers", but in manuscript partici-
pants are described as "ethnic minority women", and inclusion criteria on ClinicalTrials.gov includes
Hispanic women.
Dates of study: July 2006 to May 2010
Funding sources: "This study was supported by the Eunice Kennedy Shriver National Institute of Child
Health and Human Development (U10 HD036104 and U18 HD031206-07). This research was supported,
in part, by the intramural program of the Eunice Kennedy Shriver National Institute of Child Health and
Human Development."
El-Mohandes 2013 
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Declarations of interest: "None of the authors have any competing interests to declare."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation in a 1:1 ratio was stratified by site and initial salivary cotinine
levels. A web-based database management system was programmed to ran-
domise after entering the necessary data to verify eligibility.
Allocation concealment
(selection bias)
Low risk Randomisation is remote from research staI, so this seems appropriate (see
text from manuscript above).
Blinding (performance
bias and detection bias) 
Women and clinical staI
High risk No placebo, so participants were not blind to treatment allocation; however,
those delivering the behavioural intervention were blind to participants' treat-
ments, and the intensity of interventions/contact with participants was stan-
dardised in both groups. Those conducting telephone interviews were blind to
allocation, and smoking behaviour data "was collected through a self-admin-
istered form, completed and sealed by the participant at the end of visits 2-6
and only available to researchers at the end of the study".




Low risk Intention-to-treat appears to have been conducted adequately for smoking
outcomes, and there was relatively little data attrition for infant outcomes, so
we considered risk of bias to be low.
Selective reporting (re-
porting bias)
Unclear risk Adherence data were collected, but these were not reported. Some secondary
outcomes (regarding smoking) were not reported.
Other bias High risk In addition to the issues highlighted above, 2 women were screened and ran-
domised twice – each pregnancy counted as separate study participation, and
both were included in the analysis. Additionally, 1 woman in the NRT and CBT
group received no NRT. Given the small size of this trial, both issues could in-
troduce bias.






Methods Non-placebo, parallel-design RCT
Participants 40 healthy Australian women between 12 and 28 weeks' pregnant and smoking >= 15 cigarettes daily
with an exhaled breath CO reading of > 8 ppm
Interventions Control group: 5-minute counselling at baseline and further brief counselling (< 2 minutes' duration) at
follow-up visits.
Intervention: counselling as above plus an element concerning correct use of NRT plus 15 mg/16-hour
patches for a maximum of 12 weeks.
Outcomes Smoking cessation (point prevalence) at final antenatal visit.
Women seen "at least monthly during gestation"; also seen within 48 h of delivery when exhaled CO
and saliva sample (for cotinine) taken and by telephone at 6 weeks and 3 months.
Hotham 2006 
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Notes Exhaled CO readings used to validate point prevalence cessation at final antenatal visit. Cut point = 8
ppm CO.  Author clarification used to obtain this information as not clear in research report. No data on
smoking outcomes after childbirth are reported in the manuscript.
Dates of study: not reported
Funding sources: "This pilot study was supported by the Health Promotion Branch of the (then) South
Australian Health Commission, now the Department of Health (SA). The WCH Perinatal Pathology Fund
funded cotinine tests, performed using a competitive micro-plate immuno-assay (COTININE MICRO-
PLATE EIA)."
Declarations of interest: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated sequence
Allocation concealment
(selection bias)
Unclear risk Described as "sealed envelope system". Unclear whether envelopes opaque.
Blinding (performance
bias and detection bias) 
Women and clinical staI
High risk No placebo was used. Unclear if assessors blinded to allocation of treatments.




Low risk 14/40 withdrew from the study (35% attrition). All withdrawals included in this
analysis as women who continued to smoke.
Selective reporting (re-
porting bias)
Unclear risk Author confirmed that the following outcomes were collected: mode of de-
livery, labour interventions (if any), birthweight, Apgar scores at 1 and 5 min,
results of cord-blood analysis for pH and base excess and also for carboxy-
haemoglobin and cotinine.
Author asked to provide birthweight data to inform safety analyses.






Methods Parallel-design RCT with active and placebo patches and clinicians/researchers and participants un-
aware of allocation
Participants 30 healthy Canadian women between 12 and 24 weeks' pregnant and smoking >= 15 cigarettes daily
who want to quit smoking and could not do so in 1st trimester
Interventions 12-week course of NRT or identical placebo patches: 15 mg/18-hour patch for 8 weeks, then 10 mg/18-
hour patch for 2 weeks, and finally 5 mg/18-hour patch for 2 weeks. Behavioural counselling at baseline
and at all follow-up points. Counselling at baseline included a video explaining how to use patch; also
counselling at all follow-ups. Weekly telephone contact with women.
Intervention = active patch, control = placebo
Kapur 2001 
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Outcomes Smoking cessation (unclear if point prevalence or continuous cessation measured) 8 weeks into pro-
gramme (20 to 32 weeks into pregnancy).
Follow-up also at weeks 1 and 4 into programme with saliva and serum cotinine measured at all time
points.
Notes Primary outcome validated at 8 weeks into programme. Cotinine cut point not reported, but paper
states that "in no case was smoking cessation associate with thiocyanate levels of > 1 ug/ml".
Dates of study: not reported
Funding sources: "This study was supported by a grant from the Canadian lnstitutes of Health Research
(CIHR)."
Declarations of interest: "Gideon Koren, MD, is a Senior Scientist of the CIHR."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random number sequence - confirmed by authors.
Allocation concealment
(selection bias)
Low risk Placebo or active patches packed remotely as per the randomisation sequence
- confirmation via contact with author.
Blinding (performance
bias and detection bias) 
Women and clinical staI
Low risk Described as participants and researchers or clinicians unaware of treatment
allocation with identical active and placebo NRT patches, although most
women in the placebo group did not complete the programme.





Low risk Biochemical validation missing for approximately one-third of the sample. All








Methods Double-blind, placebo-controlled RCT
Participants 65 pregnant women, ≥ 18 years of age, between 13 and 30 weeks’ gestation, smoking ≥ 10 cigarettes
per day prior to pregnancy and 5 cigarettes per day for the preceding 7 days, English or Spanish speak-
ing, and having the intent to carry to term
Interventions Participants received bupropion SR orally once daily for 3 days followed by twice daily for a total med-
ication treatment of 12 weeks.
Both groups received behavioural interventions, which included 35-minute counselling sessions at
each of the first 2 visits (enrolment and on the quit day) and 10 minutes of smoking cessation coun-
selling at subsequent visits. Counselling sessions were delivered by a research nurse using a motiva-
tional interviewing approach.
Intervention = bupropion SR, control = placebo
Nanovskaya 2017 
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Outcomes 7-day point prevalence abstinence at 12 weeks after the quit date (end of treatment), and 36 to 38
weeks' gestation (end of pregnancy). Defined at each visit as no cigarettes (not even a puI) in the last 7
days, levels of CO in exhaled air < 4 ppm, and concentrations of cotinine in urine < 50 ng/mL.
Notes Dates of study: July 2011 to December 2016
Funding sources: "The study was supported by National Institute on Drug Abuse grant RO1 DA030998
(to G.H. and T.N.)."
Declarations of interest: "The authors report no conflict of interest."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Urn randomisation method. Balanced for 2 variables: gestational age at study
entry and number of CPD.
Allocation concealment
(selection bias)
Unclear risk Not explicitly described, so unclear.
Blinding (performance
bias and detection bias) 
Women and clinical staI
Low risk Participants, primary investigators, and research nurses were blinded to phar-
macotherapy group assignment. Implication that drug and placebo were pack-
aged similarly. Research nurses were also those that monitored smoking sta-
tus and outcomes.
Biochemically validated abstinence using CO < 4 ppm and urinary cotinine lev-




Low risk Missing outcome data balanced for both groups, for similar reasons. Women
lost to follow-up were judged to have returned to smoking.
Selective reporting (re-
porting bias)
Unclear risk Paper states that low birthweight was recorded, but no evidence of reporting.




Methods Parallel-design RCT with active and placebo NRT gum and clinicians/researchers and participants un-
aware of allocation
Participants 194 healthy, US English-/Spanish-speaking women <= 26 weeks' pregnant, smoking >= 1 cigarette daily
and aged >= 16 years
Interventions 12 weeks treatment with either 2 mg NRT gum or identical placebo. 6 weeks full treatment was fol-
lowed by 6 weeks tapering of treatment. Instructed not to chew > 20 pieces daily and to use 1 piece
of gum for each substituted cigarette. Additionally, all participants received individual counselling at
baseline and at all 8 follow-ups: 2, 35-minute counselling sessions at baseline and within 1 week of quit
date and shorter sessions at other follow-ups.
Intervention = active gum, control = placebo
Outcomes Self-reported 7-day point prevalence abstinence at 6 weeks after treatment commenced, at 32 to 35
weeks of pregnancy, and at 6 to 12 weeks after delivery. Exhaled CO of less than 8 ppm used for valida-
tion all time points.
Notes Dates of study: July 2003 to April 2007
Oncken 2008 
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Funding sources: "Supported by NIH grants R01 DA15167, GCRC grant M01 RR006192, P50 DA013334,
P50 AA015632. Nicotine Gum was provided free of charge from Glaxo-Smith Kline."
Declarations of interest: "Dr. Oncken has received consulting fees and honoraria from Pfizer (New York,
NY) for advisory board meetings. She has received at no cost nicotine and/or placebo products from
Glaxo-SmithKline (Philadelphia, PA) for smoking cessation studies (i.e., for pregnant women, post-
menopausal women). She has received grant funding from Pfizer for smoking cessation studies and
from Nabi Biopharmaceuticals (Boca Raton, FL) for a nicotine vaccine study. Dr. Kranzler has received
consulting fees from Ortho-McNeil Pharmaceuticals (Raritan, NJ), H. Lundbeck A/S (Copenhagen, Den-
mark), Forest Pharmaceuticals (St. Louis, MO), elbion NV (Leuven, Belgium), Sanofi-Aventis (Bridgewa-
ter, NJ), Solvay Pharmaceuticals (Bruxelles, Belgium), and Alkermes, Inc. (Cambridge, MA). He has re-
ceived research support from Ortho-McNeil Pharmaceuticals and Bristol-Myers Squibb Company (New
York, NY), and honoraria from Forest Pharmaceuticals and Alkermes, Inc. The other authors have no
potential conflicts of interest to disclose."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerised randomisation program to balance participant assignment into
treatment groups based on variables of maternal age, gestational age at study
entry, number of cigarettes smoked per day, health insurance (public or pri-
vate), and use of methadone maintenance
Allocation concealment
(selection bias)
Low risk Computerised allocation
Blinding (performance
bias and detection bias) 
Women and clinical staI
Low risk Placebo-controlled trial with placebo and treatment packaged in same blister
packets.
Urine anabasine/anatabine alkaloids from tobacco, which are not altered by




Low risk Perinatal outcomes for 95% of control group and 97% of intervention group
(excluding 1 from each group who withdrew consent and others lost to fol-
low-up). 
Smoking outcomes/participation at end of pregnancy for 64% of control group
and 78% of intervention group.




Low risk All adverse events reported.






Methods Parallel-design RCT with active and placebo NRT inhaler and clinicians/researchers and participants
unaware of allocation
Participants 137 healthy US English-/Spanish-speaking women smoking at least 5 cigarettes per day, 13 to 26 weeks’
gestation, ≥ 16 years of age, intending to carry their pregnancy to term, and living in a stable residence
Oncken 2019 
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Interventions 6 weeks' treatment using NICOTROL inhaler (nicotine inhalation system) delivering 4 mg of nicotine
from a porous plug containing 10 mg nicotine. Participants were encouraged to continue the use of the
inhaler as long as they were actively trying to quit smoking. Participants instructed to puI on the in-
haler 3 to 4 times per minute for up to 20 minutes and to inhale deeply in short breaths as they would
normally smoke a cigarette. Participants who smoked ≥ 10 CPD were instructed to begin with 4 to 12
cartridge inhalers per day; women who smoked 5 to 9 CPD were instructed to begin with 1 to 4 car-
tridge inhalers per day, based on an estimated 1 to 2 mg of nicotine delivery per cigarette, with each
cartridge inhaler estimated to release 4 mg of nicotine. At baseline and 1 week after quit date, partici-
pants received 35 minutes of individual smoking cessation counselling by a study nurse trained to de-
liver the counselling using a motivational interviewing approach.
Intervention = nicotine inhaler, control = placebo
Outcomes Self-reported 7-day point prevalence abstinence at 6 weeks after quit date, at 32 to 36 weeks of preg-
nancy, and at 1 and 6 months after delivery. Exhaled CO of less than 4 ppm used for validation at all
time points.
Notes Study planned to recruit 360 women, but the trial was stopped after a recommendation from the Data
and Safety Monitoring Board due to futility in detecting differences in the primary outcome.
Dates of study: August 2012 to January 2017
Funding sources: "This study was supported by National Institutes of Health (NIH) of United States
grant R01HD069314 and the Lowell P. Weicker Clinical Research at the University of Connecticut School
of Medicine. The study medication was donated by Pfizer Pharmaceuticals."
Declarations of interest: "Dr Kranzler is a member of the American Society of Clinical Psychopharma-
cology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by AbbVie, Alkermes,
Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences and is named
as an inventor on Patent Cooperation Treaty patent application 15/878,640 entitled genotype-guided
dosing of opioid agonists, filed Jan. 24, 2018. The other authors report no conflict of interest."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Urn randomisation procedure used, balanced for gestational age, history of




Unclear risk Not explicitly stated whether allocation was concealed from the research
pharmacy, so this is rated as unclear.
Blinding (performance
bias and detection bias) 
Women and clinical staI
Low risk All study personnel and participants were blinded to treatment assignment.
Inhalers were packaged in the same device to maintain blinding integrity.




Low risk Follow-up rates for smoking outcomes at 32 to 36 weeks' gestation were 58%
in placebo group and 67% in nicotine group. However, all women lost to fol-
low-up were assumed to be smoking and were included in the analysis. High
follow-up rates for birth outcomes.
Selective reporting (re-
porting bias)
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Methods Non-placebo, parallel-design RCT
Participants 181 healthy US English-speaking women between 13 and 25 weeks' pregnant, smoking >= 5 cigarettes
daily, and aged >= 18 years. Must have smoked > 100 cigarettes in lifetime.
Interventions Control group: 5 face-to-face and 1 telephone behavioural counselling sessions with booklet and sup-
port materials.
Intervention group: counselling as above but with additional focus on use of NRT. Women permitted
choice of NRT from patch, gum, or lozenge. Patch dose depended on CPD: < 10 CPD, 7 mg/16 h; 10 to 14
CPD, 14 mg/16 h; >= 15 CPD, 21 mg/16 h. Where gum or lozenge was used, one 2 mg piece was used for
each cigarette smoked daily. Maximum of 6 weeks' NRT provided, and no NRT provided when women
returned to smoking.
Outcomes Self-reported 7-day point prevalence abstinence at 38 weeks.
Also follow-up at 7 weeks after randomisation and 3 months' postpartum using self-report data.
Saliva samples for cotinine validation were collected at the intervention session that coincided with
each telephone survey from all women regardless of smoking status. Cut point for primary outcome <=
10 ng/mL. Validation data were collected at all 3 time points, but are only reported for the 2 data col-
lection points within pregnancy.
Notes Choices of NRT: 72/122 patch = 59%, 32/122 gum = 26.2% and 12/122 lozenge = 9.8%. 19 women chose
another formulation as they could not quit with initial selection (changes not recorded).
Dates of study: May 2003 to August 2005
Funding sources: "This work was supported by the National Cancer Institute (grant R01CA089053 and
operated under IND #67,259)." NRT donated by GlaxoSmithKline.
Declarations of interest: "No financial disclosures were reported by the authors of this paper."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerised random number generation
Allocation concealment
(selection bias)
Low risk StaI responsible for randomising participants used handheld computer de-
vices that kept allocation sequence from them until the point of intervention
delivery.
Blinding (performance
bias and detection bias) 
Women and clinical staI
High risk No placebo used; open-label trial. Assessors blinded to allocation.




Low risk Loss to follow-up low for perinatal outcomes (10/181 births), but more than
30% attrition for assessment of smoking status at the postnatal follow-up.




Low risk All adverse outcomes reported.
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Methods Placebo-controlled RCT with parallel-group design
Participants 11 pregnant women at least 18 years old; 14 to 26 weeks’ gestation; and currently smoking at least 1
daily cigarette. Women were excluded if they had abnormal LFTs; history of or current seizure disor-
der or closed head injury with loss of consciousness; hypersensitivity to bupropion; any psychiatric dis-
order requiring psychotropic medication; current anorexia or bulimia; monoamine oxidase use in the
past 2 weeks; major depression or risk of suicide; illicit substance use in the past 30 days; > 1 alcoholic
drink/week; unstable medical problems; multiple pregnancy; fetal structural anomaly; planned birth at
a non-affiliated hospital; communication problems or lack of transport/phone; or current use of NRT,
bupropion, or varenicline.
Interventions Bupropion SR or matching placebo. Bupropion SR was dosed at 150 mg/day for the first 3 days and 300
mg/day thereafter (150 mg twice a day). Placebo appearance, taste, and dosing instructions were iden-
tical. Participants and providers were masked to treatment group. Both groups received 4 weekly 15-
minute smoking cessation counselling sessions based on Clinical Practice Guidelines delivered by a re-
search nurse.
Outcomes The primary smoking outcome was self-reported total abstinence in the prior 7 days (7-day point
prevalence) with saliva cotinine validation at the end of treatment. Saliva cotinine assays used a cut
point of > 20 ng/mL indicating regular smoking. Exhaled CO concentration in ppm was measured at
each assessment time point using the EC-50 (Vitalograph Inc, Lenexa, KS) to indicate recent exposure to
tobacco smoke in ppm. Maternal, perinatal, and neonatal outcomes assessed included intrauterine fe-
tal death, spontaneous abortion, placental abruption, preterm birth (< 37 weeks, 0 days), pre-eclamp-
sia, maternal weight gain, birthweight, umbilical artery pH, gestational age at delivery, fetal growth re-
striction (birthweight < 10th percentile), neonatal intensive care unit admission, respiratory complica-
tions (per physician notes).
Notes The cut point for saliva cotinine is higher than the current standard.
Dates of study: April 2011 to August 2012
Funding sources: "This study was supported by the Center for Clinical and Translational Sciences (CC-
TS) funded by CTSA awarded to the University of Texas Health Science Center at Houston (UL1 RR
024148) and the Larry C. Gilstrap MD Center for Perinatal and Women’s Health Research of the Universi-
ty of Texas Medical School at Houston."
Declarations of interest: "The authors declare that there are no conflicts of interest."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomly assigned using permuted block design
Allocation concealment
(selection bias)
Unclear risk There is no description of how randomisation was operationalised, so rated as
unclear.
Blinding (performance
bias and detection bias) 
Women and clinical staI
Low risk Trial used visually identical placebos, therefore participants and those deliver-
ing the intervention were blind to treatment. It is not explicitly stated that the
outcome assessor was blinded, but this is likely to be an omission, as it seems
unlikely given placebo control and randomisation that the assessor would not
be blinded.
Validated data are presented for cessation outcomes, and although these use
a high cut point (20 ng/mL for saliva), individual participant saliva cotinine
Stotts 2015 
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readings are reported and these could be used to evaluate findings against a




Low risk Use of an intention-to-treat analysis was not specifically stated (this would ef-
fectively mean that there was no loss of data); however, at the main outcome
point for smoking cessation, outcome data on all 11 participants are reported
within the groups to which they had been randomised.
Selective reporting (re-
porting bias)





Methods Parallel-design RCT with active and placebo patches and clinicians/researchers and participants un-
aware of allocation
Participants 250 healthy Danish women < 22 weeks' pregnant and smoking >= 10 cigarettes daily
Interventions 11-week course of NRT or identical placebo patches: 15 mg/16 h for 8 weeks then 10 mg/16 h for 3
weeks plus behavioural counselling and information pamphlet.
Intervention = active patch, control = placebo
Outcomes Self-reported abstinence of >= 7 days at 2nd, 3rd, and 4th prenatal visits (4 weeks prior to delivery). 
Follow-ups at times above and also by telephone at 3 months and 1 year after delivery.
Notes Saliva cotinine level < 26 ng/mL at the 4th visit (4 weeks prior to expected delivery date) used to vali-
date reported smoking cessation. The test used could not detect lower than 20 ng/mL (data verified by
communication with author). Only self-report data were collected after childbirth.
Dates of study: October 1995 to October 1997
Funding sources: "This study was supported by the Danish Cancer Society and the Ministry of Health
(The National Health Fund supported this study for Research and Development). Pharmacia & Upjohn
provided nicotine patches."
Declarations of interest: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomised list in balanced blocks
Allocation concealment
(selection bias)
Low risk Placebo-controlled trial with allocation coded until the end of data collection
Blinding (performance
bias and detection bias) 
Women and clinical staI
Low risk Placebo-controlled trial with allocation coded until the end of data collection.
Used cut point that is higher than currently accepted and biochemical test that
could not detect levels of cotinine of < 20 ng/mL (data obtained from authors).
Some respondents reporting smoking cessation may have actually been still
smoking, and the biochemical test would not detect this. We dealt with this by
using self-report data in primary analyses and investigating the impact of us-
ing biochemically validated data in a sensitivity analysis.
Wisborg 2000 
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Low risk Small loss to follow-up, but missing data treated in this analysis as women
who continued to smoke. The treatment allocation of 7 miscarriages could
not be determined, though as this was a secondary outcome, the study was
deemed to be at low risk of bias for this criterion.
Selective reporting (re-
porting bias)
Low risk Adverse outcomes reported.





CPD: cigarettes per day
LFTs: liver function tests
NRT: nicotine replacement therapy
ppm: parts per million
RCT: randomised controlled trial
SR: sustained release
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Eades 2012 Quasi-randomised, as women were allocated to intervention or control in 'control' or 'intervention'
weeks with the nature of individual weeks determined by random allocation (but outcomes being
monitored at the level of individual women). We judged that it was not possible to attribute treat-
ment effects in the intervention arm to NRT because NRT was offered as part of a multimodal inter-
vention that offered more behavioural support (in addition to the NRT) to participants in the inter-
vention group. Additionally, NRT was only offered to those intervention group women who made
2 failed quit attempts after receiving behavioural components of the intervention, and, in the pre-
sentation of outcomes from the study, women who accepted the offer of NRT at this stage could
not be differentiated from other intervention group women.
Gould 2019 Tested a multimodal intervention, making it impossible to identify the individual effect NRT might
have on smoking cessation.
Hegaard 2003 Quasi-random allocation/sequence generation of participants (by birth date).
It was not possible to attribute treatment effects in the intervention arm solely to NRT because NRT
was offered as part of a multimodal intervention that differed between trial arms.
At randomisation, participants did not have to agree to use NRT; of 327 women randomised to the
intervention group, only 75 accepted an offer of NRT. Smoking outcomes were not reported within
the subgroup of those using NRT, so it was not clear if NRT was responsible for smoking outcomes.
NCT00744913 Trial withdrawn due to recruitment problems.
NCT00888979 Non-randomised study in which all women were provided nicotine inhaler. Feasibility study inves-
tigating the impact of nicotine inhaler on smoking cessation.
Oncken 2009a Non-randomised cohort study that investigated the impacts of nicotine patches or nasal spray on
nicotine exposure in pregnant women.
NRT: nicotine replacement therapy
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Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title SISTAQUIT (Supporting Indigenous Smokers to Assist Quitting)
A cluster randomised controlled trial to improve strategies for the management of smoking cessa-
tion in pregnant Aboriginal and/or Torres Strait Islander women
Methods Cluster-randomised controlled trial
Participants Pregnant; up to and including 32 weeks' gestation; Aboriginal and/or Torres Strait Islander (or ex-
pectant mothers of an Aboriginal and/or Torres Strait Islander baby); smoke tobacco (any amount);
able to provide informed consent; attending antenatal care at 1 of the 30 Aboriginal Medical Ser-
vices and General Practices participating in SISTAQUIT.
Interventions • Culturally appropriate training in smoking cessation care for health providers (2 hours)
• Health providers include general practitioners, midwives, nurses, Tobacco & Aboriginal Health
Workers
• Ideally, all health providers at each service/GP practice (especially those who provide care for
pregnant women) will undertake the training
• Targeted educational resources: participant booklet and flip chart, health provider manual
• Oral NRT
• Participant smoking cessation information video loop
Outcomes Smoking cessation status self-report, 4 and 12 weeks after recruitment to the trial, and 36 weeks'
gestation
Starting date July 2018
Contact information Gillian Gould; gillian.gould@newcastle.edu.au




Trial name or title Comparison of the effectiveness of treatment with nicotine patches versus support behavior in
smoking cessation in pregnant women
Methods Placebo-randomised, double-blind, controlled trial
Participants Pregnant women who agreed to set a quit date, 16 to 50 years of age, 12 to 24 weeks' gestation,
smoked 10 or more cigarettes daily before pregnancy, currently smoking 5 or more cigarettes daily
Interventions Nicotine patches (15 mg/16 hours)
Outcomes Abstinence from the date of smoking cessation until delivery
Starting date March 2019
Contact information Zohre Gozidehkar; zohre.gozidehkar@gmail.com
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Trial name or title Helping pregnant smokers quit: a multi-centre study of electronic cigarettes and nicotine patches
Methods Multicentre, open-label randomised controlled trial
Participants Daily smokers; 12 to 24 weeks pregnant; wants help with stopping smoking; willing to be ran-
domised to use either NRT or EC (to avoid selective dropout and contamination); willing to receive
6 weekly support calls over the phone plus 2 follow-up calls; speaks English (to allow data collec-
tion via phone); aged 18 years or over
Interventions Participants randomised (1:1) to receive either nicotine patches for up to 8 weeks (15 mg/16 hours)
or an e-cigarette starter pack. Both groups will receive weekly telephone support for 6 weeks from
specialist stop-smoking advisors.
Outcomes Prolonged abstinence rates at the end of pregnancy, defined as per Russell Standard (up to 5 laps-
es allowed from 2 weeks after the target quit day until end of pregnancy, with no smoking at all
during the previous week at the time of follow-up), and verified by salivary cotinine (< 15 ng/mL)
for those not reporting using any nicotine product and anabasine (< 1 ng/mL) for those reporting
other forms of nicotine use.
Starting date 01 May 2017
Contact information Dr Dunja Przulj
Health and Lifestyle Research Unit









Trial name or title Bupropion for smoking cessation in pregnancy
Methods Placebo-randomised, double-blind, controlled trial
Participants Smoked at least 1 puI in the past 7 days, confirmed viable gestation
Interventions Study medication (150 mg bupropion SR) daily for 14 days. Women still smoking at 2 and 4 weeks
were encouraged to increase their medication to 2 times per day (150 mg twice daily).
Outcomes Biologically verified smoking cessation or reduction at 8 weeks and at delivery
Starting date October 2001
Contact information Hugh S Miller
Notes The record (updated June 2013) states that the study was completed in January 2004. No results
were identified, and we were unable to contact the author.
NCT01875172 
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Trial name or title Placebo-controlled trial of bupropion for smoking cessation in pregnant women (BIBS)
Methods Placebo-randomised, parallel-group, controlled trial
Participants Pregnant at 13 to 24 weeks' gestation and > 18 years of age; currently smoking at least 5 cigarettes
per day for the preceding 7 days and wants to quit smoking; able to speak and read English at a 6th
grade level or higher, using the Slosson Oral Reading Test (SORT); committed to remaining in the
geographic area for at least 3 months postpartum; able to sign written informed consent and com-
mit to completing the procedures involved in the study.
Interventions Bupropion 150 mg twice daily for 10 weeks or a visually identical placebo
Outcomes 7-day point prevalence abstinence from smoking; number of cigarettes smoked; frequency of mod-
erate or severe side effects; birth outcomes; smoking frequency after 10-week treatment phase.
Starting date October 2014
Contact information Timothy S Pond; timpond@pennmedicine.upenn.edu
Leah Zindel; zindel@pennmedicine.upenn.edu
Notes Aims to recruit 360 participants by December 2021.
NCT02188459 
EC: electronic cigarettes




D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Nicotine replacement therapy versus control





Statistical method Effect size
1 Validated cessation in lat-
er pregnancy (subgrouped by
comparator type)
9 2336 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.08, 1.74]
1.1 Placebo-controlled trials 6 2063 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.95, 1.55]
1.2 Non-placebo-controlled
trials
3 273 Risk Ratio (M-H, Fixed, 95% CI) 8.55 [2.05, 35.71]
2 Validated cessation in lat-
er pregnancy (subgrouped by
NRT type)
9 2336 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.08, 1.74]
2.1 Long-acting NRT 7 2005 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [1.16, 2.01]
2.2 Fast-acting NRT 2 331 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.55, 1.51]
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Statistical method Effect size
3 Self-report cessation at 3 or
6 months after childbirth
3 625 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.84, 1.78]
3.1 Placebo-controlled trials 2 444 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.75, 1.77]
3.2 Non-placebo-controlled
trials
1 181 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.69, 3.03]
4 Self-report cessation at 12
months after childbirth
2 1296 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.97, 1.88]
5 Miscarriage and sponta-
neous abortion
5 1916 Risk Ratio (M-H, Random, 95% CI) 1.60 [0.53, 4.83]
6 Stillbirth 4 1777 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.54, 2.84]
7 Mean birthweight (g) 7 2202 Mean Difference (IV, Random, 95% CI) 99.73 [-6.65, 206.10]
7.1 Placebo-controlled trials 5 1986 Mean Difference (IV, Random, 95% CI) 119.01 [-4.24, 242.25]
7.2 Non-placebo-controlled
trials
2 216 Mean Difference (IV, Random, 95% CI) 36.39 [-256.19, 328.98]
8 Low birthweight (< 2500 g) 7 2171 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.39, 1.20]
8.1 Placebo-controlled trials 5 1955 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.28, 1.10]
8.2 Non-placebo-controlled
trials
2 216 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.61, 2.98]
9 Preterm birth (birth < 37
weeks)
7 2182 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.59, 1.11]
9.1 Placebo-controlled trials 5 1955 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.51, 1.06]
9.2 Non-placebo-controlled
trials
2 227 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.62, 2.35]
10 Neonatal intensive care
unit admissions
4 1756 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.64, 1.27]
11 Neonatal death 4 1746 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.17, 2.62]
12 Congenital abnormalities 2 1401 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.36, 1.48]
13 Caesarean section 2 1401 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.83, 1.69]
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Analysis 1.1.   Comparison 1 Nicotine replacement therapy versus control, Outcome
1 Validated cessation in later pregnancy (subgrouped by comparator type).
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.1 Placebo-controlled trials  
Oncken 2019 7/70 12/67 11.64% 0.56[0.23,1.33]
Oncken 2008 18/100 14/94 13.7% 1.21[0.64,2.29]
Coleman 2012 49/521 40/529 37.68% 1.24[0.83,1.86]
Berlin 2014 25/203 19/199 18.21% 1.29[0.73,2.27]
Wisborg 2000 22/124 17/126 16.01% 1.31[0.73,2.35]
Kapur 2001 4/17 0/13 0.53% 7[0.41,119.46]
Subtotal (95% CI) 1035 1028 97.77% 1.21[0.95,1.55]
Total events: 125 (NRT), 102 (Control)  
Heterogeneity: Tau2=0; Chi2=4.65, df=5(P=0.46); I2=0%  
Test for overall effect: Z=1.51(P=0.13)  
   
1.1.2 Non-placebo-controlled trials  
Hotham 2006 3/20 0/20 0.47% 7[0.38,127.32]
Pollak 2007 17/122 1/59 1.28% 8.22[1.12,60.31]
El-Mohandes 2013 5/26 0/26 0.47% 11[0.64,189.31]
Subtotal (95% CI) 168 105 2.23% 8.55[2.05,35.71]
Total events: 25 (NRT), 1 (Control)  
Heterogeneity: Tau2=0; Chi2=0.05, df=2(P=0.98); I2=0%  
Test for overall effect: Z=2.94(P=0)  
   
Total (95% CI) 1203 1133 100% 1.37[1.08,1.74]
Total events: 150 (NRT), 103 (Control)  
Heterogeneity: Tau2=0; Chi2=12.19, df=8(P=0.14); I2=34.4%  
Test for overall effect: Z=2.6(P=0.01)  
Test for subgroup differences: Chi2=6.99, df=1 (P=0.01), I2=85.7%  
Favours control 100.1 50.2 20.5 1 Favours NRT
 
 
Analysis 1.2.   Comparison 1 Nicotine replacement therapy versus control,
Outcome 2 Validated cessation in later pregnancy (subgrouped by NRT type).
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.2.1 Long-acting NRT  
Berlin 2014 25/203 19/199 18.21% 1.29[0.73,2.27]
Coleman 2012 49/521 40/529 37.68% 1.24[0.83,1.86]
El-Mohandes 2013 5/26 0/26 0.47% 11[0.64,189.31]
Hotham 2006 3/20 0/20 0.47% 7[0.38,127.32]
Kapur 2001 4/17 0/13 0.53% 7[0.41,119.46]
Pollak 2007 17/122 1/59 1.28% 8.22[1.12,60.31]
Wisborg 2000 22/124 17/126 16.01% 1.31[0.73,2.35]
Subtotal (95% CI) 1033 972 74.66% 1.53[1.16,2.01]
Total events: 125 (NRT), 77 (Control)  
Heterogeneity: Tau2=0; Chi2=8.38, df=6(P=0.21); I2=28.42%  
Test for overall effect: Z=3.05(P=0)  
   
1.2.2 Fast-acting NRT  
Favours [Control] 1000.01 100.1 1 Favours [NRT]
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Oncken 2008 18/100 14/94 13.7% 1.21[0.64,2.29]
Oncken 2019 7/70 12/67 11.64% 0.56[0.23,1.33]
Subtotal (95% CI) 170 161 25.34% 0.91[0.55,1.51]
Total events: 25 (NRT), 26 (Control)  
Heterogeneity: Tau2=0; Chi2=1.97, df=1(P=0.16); I2=49.2%  
Test for overall effect: Z=0.37(P=0.71)  
   
Total (95% CI) 1203 1133 100% 1.37[1.08,1.74]
Total events: 150 (NRT), 103 (Control)  
Heterogeneity: Tau2=0; Chi2=12.19, df=8(P=0.14); I2=34.4%  
Test for overall effect: Z=2.6(P=0.01)  
Test for subgroup differences: Chi2=3.13, df=1 (P=0.08), I2=68.06%  
Favours [Control] 1000.01 100.1 1 Favours [NRT]
 
 
Analysis 1.3.   Comparison 1 Nicotine replacement therapy versus control,
Outcome 3 Self-report cessation at 3 or 6 months aPer childbirth.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.3.1 Placebo-controlled trials  
Oncken 2008 11/100 9/94 21.64% 1.15[0.5,2.65]
Wisborg 2000 26/124 23/126 53.21% 1.15[0.69,1.9]
Subtotal (95% CI) 224 220 74.85% 1.15[0.75,1.77]
Total events: 37 (NRT), 32 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=1); I2=0%  
Test for overall effect: Z=0.63(P=0.53)  
   
1.3.2 Non-placebo-controlled trials  
Pollak 2007 24/122 8/59 25.15% 1.45[0.69,3.03]
Subtotal (95% CI) 122 59 25.15% 1.45[0.69,3.03]
Total events: 24 (NRT), 8 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.99(P=0.32)  
   
Total (95% CI) 346 279 100% 1.22[0.84,1.78]
Total events: 61 (NRT), 40 (Control)  
Heterogeneity: Tau2=0; Chi2=0.29, df=2(P=0.87); I2=0%  
Test for overall effect: Z=1.07(P=0.29)  
Test for subgroup differences: Chi2=0.29, df=1 (P=0.59), I2=0%  
Favours control 1 Favours NRT
 
 
Analysis 1.4.   Comparison 1 Nicotine replacement therapy versus
control, Outcome 4 Self-report cessation at 12 months aPer childbirth.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Coleman 2012 55/521 37/529 66.93% 1.51[1.01,2.25]
Favours control 1000.01 100.1 1 Favours NRT
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Wisborg 2000 19/124 18/122 33.07% 1.04[0.57,1.88]
   
Total (95% CI) 645 651 100% 1.35[0.97,1.88]
Total events: 74 (NRT), 55 (Control)  
Heterogeneity: Tau2=0; Chi2=1.05, df=1(P=0.31); I2=4.77%  
Test for overall effect: Z=1.8(P=0.07)  
Favours control 1000.01 100.1 1 Favours NRT
 
 
Analysis 1.5.   Comparison 1 Nicotine replacement therapy versus
control, Outcome 5 Miscarriage and spontaneous abortion.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Berlin 2014 1/189 1/188 16% 0.99[0.06,15.79]
Coleman 2012 3/515 2/521 38.37% 1.52[0.25,9.04]
Oncken 2008 2/100 1/91 21.52% 1.82[0.17,19.74]
Oncken 2019 1/67 0/67 12.07% 3[0.12,72.35]
Pollak 2007 1/119 0/59 12.05% 1.5[0.06,36.27]
   
Total (95% CI) 990 926 100% 1.6[0.53,4.83]
Total events: 8 (NRT), 4 (Control)  
Heterogeneity: Tau2=0; Chi2=0.28, df=4(P=0.99); I2=0%  
Test for overall effect: Z=0.83(P=0.41)  
Favours NRT 10000.001 100.1 1 Favours control
 
 
Analysis 1.6.   Comparison 1 Nicotine replacement therapy versus control, Outcome 6 Stillbirth.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Berlin 2014 5/189 6/188 50.16% 0.83[0.26,2.67]
Coleman 2012 5/512 2/519 25.66% 2.53[0.49,13]
Oncken 2008 2/100 1/91 12.08% 1.82[0.17,19.74]
Pollak 2007 2/119 1/59 12.11% 0.99[0.09,10.72]
   
Total (95% CI) 920 857 100% 1.24[0.54,2.84]
Total events: 14 (NRT), 10 (Control)  
Heterogeneity: Tau2=0; Chi2=1.33, df=3(P=0.72); I2=0%  
Test for overall effect: Z=0.51(P=0.61)  
Favours NRT 1000.01 100.1 1 Favours control
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Analysis 1.7.   Comparison 1 Nicotine replacement therapy versus control, Outcome 7 Mean birthweight (g).
Study or subgroup NRT Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.7.1 Placebo-controlled trials  
Berlin 2014 189 3078 (648) 188 3024 (582) 17.24% 54[-70.32,178.32]
Coleman 2012 521 3180 (610) 521 3200 (590) 20.39% -20[-92.87,52.87]
Oncken 2008 93 3287 (566) 90 2950 (653) 13.86% 337[159.71,514.29]
Oncken 2019 67 3141 (562) 67 3037 (584) 12.88% 104[-90.07,298.07]
Wisborg 2000 124 3457 (605) 126 3271 (605) 15.57% 186[36,336]
Subtotal *** 994   992   79.93% 119.01[-4.24,242.25]
Heterogeneity: Tau2=14376; Chi2=16.92, df=4(P=0); I2=76.36%  
Test for overall effect: Z=1.89(P=0.06)  
   
1.7.2 Non-placebo-controlled trials  
El-Mohandes 2013 25 3203 (588) 25 2997 (482) 8.14% 206[-92.04,504.04]
Pollak 2007 109 3053 (681) 57 3148 (648) 11.93% -95[-306.29,116.29]
Subtotal *** 134   82   20.07% 36.39[-256.19,328.98]
Heterogeneity: Tau2=27928.43; Chi2=2.61, df=1(P=0.11); I2=61.65%  
Test for overall effect: Z=0.24(P=0.81)  
   
Total *** 1128   1074   100% 99.73[-6.65,206.1]
Heterogeneity: Tau2=13067.68; Chi2=19.88, df=6(P=0); I2=69.83%  
Test for overall effect: Z=1.84(P=0.07)  
Test for subgroup differences: Chi2=0.26, df=1 (P=0.61), I2=0%  
Favours control 200100-200 -100 0 Favours NRT
 
 
Analysis 1.8.   Comparison 1 Nicotine replacement therapy versus control, Outcome 8 Low birthweight (< 2500 g).
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.8.1 Placebo-controlled trials  
Berlin 2014 25/189 33/188 20.52% 0.75[0.47,1.22]
Coleman 2012 56/507 43/517 21.77% 1.33[0.91,1.94]
Oncken 2008 2/93 16/85 9.23% 0.11[0.03,0.48]
Oncken 2019 4/67 10/67 12.34% 0.4[0.13,1.21]
Wisborg 2000 4/120 11/122 12.26% 0.37[0.12,1.13]
Subtotal (95% CI) 976 979 76.11% 0.55[0.28,1.1]
Total events: 91 (NRT), 113 (Control)  
Heterogeneity: Tau2=0.42; Chi2=17.24, df=4(P=0); I2=76.8%  
Test for overall effect: Z=1.7(P=0.09)  
   
1.8.2 Non-placebo-controlled trials  
El-Mohandes 2013 3/25 4/25 9.63% 0.75[0.19,3.01]
Pollak 2007 17/109 5/57 14.26% 1.78[0.69,4.57]
Subtotal (95% CI) 134 82 23.89% 1.35[0.61,2.98]
Total events: 20 (NRT), 9 (Control)  
Heterogeneity: Tau2=0.01; Chi2=1.02, df=1(P=0.31); I2=1.68%  
Test for overall effect: Z=0.75(P=0.46)  
   
Total (95% CI) 1110 1061 100% 0.69[0.39,1.2]
Total events: 111 (NRT), 122 (Control)  
Favours NRT 1000.01 100.1 1 Favours control
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0.33; Chi2=19.28, df=6(P=0); I2=68.88%  
Test for overall effect: Z=1.33(P=0.18)  
Test for subgroup differences: Chi2=2.82, df=1 (P=0.09), I2=64.56%  
Favours NRT 1000.01 100.1 1 Favours control
 
 
Analysis 1.9.   Comparison 1 Nicotine replacement therapy
versus control, Outcome 9 Preterm birth (birth < 37 weeks).
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.9.1 Placebo-controlled trials  
Berlin 2014 19/189 20/188 20.03% 0.94[0.52,1.71]
Coleman 2012 40/507 45/517 31.97% 0.91[0.6,1.36]
Oncken 2008 7/93 16/85 11.8% 0.4[0.17,0.92]
Oncken 2019 3/67 10/67 5.91% 0.3[0.09,1.04]
Wisborg 2000 10/120 12/122 12.73% 0.85[0.38,1.89]
Subtotal (95% CI) 976 979 82.43% 0.74[0.51,1.06]
Total events: 79 (NRT), 103 (Control)  
Heterogeneity: Tau2=0.05; Chi2=5.68, df=4(P=0.22); I2=29.61%  
Test for overall effect: Z=1.64(P=0.1)  
   
1.9.2 Non-placebo-controlled trials  
El-Mohandes 2013 1/25 2/25 1.79% 0.5[0.05,5.17]
Pollak 2007 24/119 9/58 15.78% 1.3[0.65,2.61]
Subtotal (95% CI) 144 83 17.57% 1.2[0.62,2.35]
Total events: 25 (NRT), 11 (Control)  
Heterogeneity: Tau2=0; Chi2=0.59, df=1(P=0.44); I2=0%  
Test for overall effect: Z=0.54(P=0.59)  
   
Total (95% CI) 1120 1062 100% 0.81[0.59,1.11]
Total events: 104 (NRT), 114 (Control)  
Heterogeneity: Tau2=0.04; Chi2=7.63, df=6(P=0.27); I2=21.39%  
Test for overall effect: Z=1.33(P=0.18)  
Test for subgroup differences: Chi2=1.58, df=1 (P=0.21), I2=36.78%  
Favours NRT 1000.01 100.1 1 Favours control
 
 
Analysis 1.10.   Comparison 1 Nicotine replacement therapy versus
control, Outcome 10 Neonatal intensive care unit admissions.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Berlin 2014 10/189 13/188 18.64% 0.77[0.34,1.7]
Coleman 2012 33/507 35/517 56.4% 0.96[0.61,1.52]
Oncken 2008 7/93 11/85 14.67% 0.58[0.24,1.43]
Pollak 2007 13/119 4/58 10.29% 1.58[0.54,4.64]
   
Total (95% CI) 908 848 100% 0.9[0.64,1.27]
Favours NRT 1000.01 100.1 1 Favours control
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Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 63 (NRT), 63 (Control)  
Heterogeneity: Tau2=0; Chi2=2.2, df=3(P=0.53); I2=0%  
Test for overall effect: Z=0.59(P=0.55)  
Favours NRT 1000.01 100.1 1 Favours control
 
 
Analysis 1.11.   Comparison 1 Nicotine replacement therapy versus control, Outcome 11 Neonatal death.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Berlin 2014 2/189 0/188 20.72% 4.97[0.24,102.91]
Coleman 2012 0/507 2/517 20.67% 0.2[0.01,4.24]
Oncken 2008 1/93 2/85 33.52% 0.46[0.04,4.95]
Pollak 2007 1/109 1/58 25.09% 0.53[0.03,8.35]
   
Total (95% CI) 898 848 100% 0.66[0.17,2.62]
Total events: 4 (NRT), 5 (Control)  
Heterogeneity: Tau2=0; Chi2=2.42, df=3(P=0.49); I2=0%  
Test for overall effect: Z=0.59(P=0.55)  
Favours NRT 200.05 50.2 1 Favours control
 
 
Analysis 1.12.   Comparison 1 Nicotine replacement therapy versus control, Outcome 12 Congenital abnormalities.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Berlin 2014 4/189 5/188 29.53% 0.8[0.22,2.92]
Coleman 2012 9/507 13/517 70.47% 0.71[0.3,1.64]
   
Total (95% CI) 696 705 100% 0.73[0.36,1.48]
Total events: 13 (NRT), 18 (Control)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.88); I2=0%  
Test for overall effect: Z=0.87(P=0.39)  
Favours NRT 1000.01 100.1 1 Favours Control
 
 
Analysis 1.13.   Comparison 1 Nicotine replacement therapy versus control, Outcome 13 Caesarean section.
Study or subgroup NRT Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Berlin 2014 28/189 30/188 35.97% 0.93[0.58,1.49]
Coleman 2012 105/507 79/517 64.03% 1.36[1.04,1.77]
   
Total (95% CI) 696 705 100% 1.18[0.83,1.69]
Total events: 133 (NRT), 109 (Control)  
Heterogeneity: Tau2=0.03; Chi2=1.87, df=1(P=0.17); I2=46.41%  
Test for overall effect: Z=0.92(P=0.36)  
Favours NRT 1000.01 100.1 1 Favours control
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Comparison 2.   Bupropion versus control





Statistical method Effect size
1 Validated cessation in later preg-
nancy
2 76 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.21, 2.64]
2 Mean birthweight (g) 2 68 Mean Difference (IV, Random, 95% CI) 122.64 [-98.82, 344.10]
 
 
Analysis 2.1.   Comparison 2 Bupropion versus control, Outcome 1 Validated cessation in later pregnancy.
Study or subgroup Bupropion Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Stotts 2015 0/5 2/6 45.45% 0.23[0.01,3.97]
Nanovskaya 2017 3/30 3/35 54.55% 1.17[0.25,5.36]
   
Total (95% CI) 35 41 100% 0.74[0.21,2.64]
Total events: 3 (Bupropion), 5 (Control)  
Heterogeneity: Tau2=0; Chi2=0.98, df=1(P=0.32); I2=0%  
Test for overall effect: Z=0.46(P=0.65)  
Favours [Control] 1000.01 100.1 1 Favours [Bupropion]
 
 
Analysis 2.2.   Comparison 2 Bupropion versus control, Outcome 2 Mean birthweight (g).
Study or subgroup Bupropion Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Nanovskaya 2017 27 3223 (501) 30 3111 (543) 66.76% 112[-159.05,383.05]
Stotts 2015 5 3127 (119) 6 2983 (462) 33.24% 144[-240.1,528.1]
   
Total *** 32   36   100% 122.64[-98.82,344.1]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=1.09(P=0.28)  
Favours control 400200-400 -200 0 Favours Bupropion
 
 
A D D I T I O N A L   T A B L E S
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NRT Control NRT Control NRT Control
Wisborg 2000 1a 7a - - - - - - - - 120 122
 
Pollak 2007 2  0 1 0 2 1 0 0 8 1 1 0 109 57
Oncken 2008 Women with multiple
births were excluded.
2 1 2 1 0 3b 3 4 0 0 93 85
 
Coleman 2012 4 8 3 2 5 2 1 0 4 10 1 0 503 507
El-Mohandes 2013 0 0 0 0 0 0 0 0 1 1 0 0 25 25
Berlin 2014 3 4 1 1 4 5 1c 1c 3 0 0 0 189d 188
Table 1.   Distribution of twin births and fetal losses within singleton pregnancies in nicotine replacement therapy and control groups  (Continued)
NRT: nicotine replacement therapy
aThe treatment allocation of the twin pregnancy and miscarriages is unknown.
bAuthors confirmed that all terminations were done for social reasons and that fetus was thought to be normal.
cDone for medical problems judged incompatible with birth survival.
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Study Adherence with offered regimen as a per-
centage of complete course
Adherence with offered regimen in terms of period of use
Wisborg 2000 Complete adherence with 11-week course:
nicotine group = 11%, placebo = 7%. Partial ad-
herence (up to 8 weeks' use): nicotine group =
17%, placebo = 8%.
Median number patches (ranges): nicotine group = 14 (0 to
77), median = approximately 2 weeks; placebo = 7 (0 to 77),
median = approximately 1 week.
Kapur 2001 In the nicotine group, 4/17 (23.5%) completed
the 14-week programme. In the placebo group,
no participants completed the programme.
In the nicotine group, 4/17 (23.5%) completed the 14-week
programme; 3/17 (17.6%) used the patch for at least 3 weeks;
and 10/17 (58.8%) used the patch for less than 1 week.
In the placebo group, no participants completed the pro-
gramme; 3/13 (23%) used the patch for between 4 and 5
weeks; and 10/13 (76.9%) used the patch for < 1 week.
Hotham 2006 25% (5) participants complied fully with proto-
col: "continuous patch use till 12 weeks or con-
fident that abstinence achieved or adverse re-
action experienced".
50% (10) of participants used NRT for 6 weeks or less.
Pollak 2007 Difficult to ascertain from manuscript. A sec-
ondary publication reported that 29% of par-
ticipants used NRT as directed for intended 6-
week programme (Fish 2009).
Means of reported periods of use:
• Patch = 23.4 patches = 3.3 weeks
• Gum = 8 days
• Lozenge = 4 days
Oncken 2008 Not clearly reported. The nicotine group used gum for a mean (SD) of 37.8 (3.8)
days (i.e. just > 5 weeks). The placebo group used gum for a
mean (SD) of 29.9 (3.4) days (i.e. just > 4 weeks).
Coleman 2012 Limited compliance with the intervention. On-
ly 7.2% of women (35 of 485) assigned to re-
ceive NRT and 2.8% (14 of 496) assigned to re-
ceive placebo reported using trial medications
for more than 1 month (2 months represented
a complete course); rates of use of non-study
NRT were very low. Most participants had no
additional contact, either face-to-face or by
text  message, with smoking cessation advi-
sors; amongst those who did, the frequency of
contact was similar in the 2 groups.
Most participants discontinued patches after using them for
only a short period: in the nicotine group 60.1% of partici-
pants used patches for no longer than 2 weeks, whilst in the
placebo patch group this figure was 76.8%.
Berlin 2014 In contrast to other studies, women were is-
sued with a much longer course of transdermal
patches, i.e. from women's quit dates to their
delivery.
Compliance was measured using self-report-
ed data on patches used between study visits
and was obtained at 1016 study visits from 307
(76%) participants: 164 (84%) in the NRT group
and 143 (72%) in the placebo group.
Median (IQR) reported patch use was 85%
(56% to 99%) in the NRT group and 83% (56%
to 95%) in the placebo group. However, it is
not clear how these figures relate to the rate
with which participants discontinued the in-
This was not reported, but it has less meaning for this RCT, as
women started using patches at different points in pregnan-
cy and continued until childbirth.
Table 2.   Adherence with nicotine replacement therapy regimens 
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tervention. Overall, 225 (60.0%) of participants
stopped using trial treatments: 105 (51.7%) in
the NRT group and 60.3% in the placebo group.
Oncken 2019 Not clearly reported. The nicotine group used the inhaler for a mean (SD) of 36.39
(23.92) days (i.e. just > 5 weeks) and used a mean (SD) of 1.70
(1.19) cartridges per day. The placebo group used the inhaler
for a mean (SD) of 34.11 (20.54) days (i.e. just < 5 weeks) and
used a mean (SD) of 1.81 (1.62) cartridges per day. Neither
of these were statistically significant differences between
groups (number of days, P = 0.587; number of cartridges, P
= 0.701). Compliance with the inhaler during treatment was
69% in the placebo group and 70% in the nicotine group.
Table 2.   Adherence with nicotine replacement therapy regimens  (Continued)
IQR: interquartile range
NRT: nicotine replacement therapy
RCT: randomised controlled trial
SD: standard deviation
 
W H A T ' S   N E W
 
Date Event Description
29 August 2019 New citation required but conclusions
have not changed
One new study added to nicotine replacement therapy com-
parison, Oncken 2019, and one new study added to bupropion
comparison, Nanovskaya 2017. Neither of these additions led to
changes in the overall conclusions.
29 August 2019 New search has been performed Search updated and two new studies added, one of nicotine
replacement therapy, Oncken 2019, and one of bupropion,
Nanovskaya 2017.
 
H I S T O R Y
Review first published: Issue 9, 2012
 
Date Event Description
11 July 2015 New citation required but conclusions
have not changed
Review updated.
This update looked for both trials of pharmacotherapies and al-
so of Electronic Nicotine Delivery Systems (ENDS) used for smok-
ing cessation in pregnancy; it found mainly nicotine replacement
therapy (NRT) trials with one bupropion trial which randomised
only 11 pregnant smokers. A total of nine trials are included in
this update.
The conclusions are largely the same, although there is now
more evidence to suggest that NRT used in pregnancy increases
smoking cessation rates measured in late pregnancy by approx-
imately 40%. There is evidence, suggesting that when potential-
ly-biased, non-placebo RCTs are excluded from analyses, NRT is
no more effective than placebo.
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Date Event Description
11 July 2015 New search has been performed Search updated. Three new trials included in this update (Berlin
2014; El-Mohandes 2013; Stotts 2015).
 
C O N T R I B U T I O N S   O F   A U T H O R S
All review authors contributed to the refreshed protocol write-up and registration (Claire 2019b). All review authors also commented on
the final draC of the updated review aCer Ravinder Claire (RC) had produced an initial draC, and RC finalised the text. Review authors
RC and Tim Coleman (TC) independently inspected the search results and selected papers for inclusion in the review update. RC and TC
extracted data from papers newly included in this update, with any disagreements resolved through discussion with Jo Leonardi-Bee (JLB).
RC contacted authors of ongoing studies as appropriate and also entered data into Review Manager 5 soCware. RC and TC assessed the
risk of bias for both newly included studies.
D E C L A R A T I O N S   O F   I N T E R E S T
RC has no known conflicts of interest.
CC is a recipient of an Australian National Health and Medical Research Council (NHMRC) Career Development Fellowship to support work
around life-course approaches to improving health equity in the perinatal period for Aboriginal parents. She has also received an NHMRC
grant to co-design perinatal strategies to support Aboriginal parents experiencing complex trauma. CC is the contact/lead author for a
Cochrane Review entitled 'Psychosocial interventions to promote smoking cessation in pregnancy' and co-author on an editorial calling
for Australian researchers to oppose tobacco industry funding for smoking research. None of this is deemed to be a conflict of interest.
MD has no known conflicts of interest.
SC is a co-applicant on, and is employed by, funding for a National Institute for Health Research (NIHR) Programme Grant for Applied
Research that includes conducting this review. She was previously employed by funding for the SNAP (Smoking Nicotine and Pregnancy)
Trial, which is included in this review. She did not assess risk of bias for this trial.
IB declares occasional honoraria from Pfizer Ltd for consultancy, participation in board meeting, and presentations in the last three years
fully independent of the current work.
JLB reports personal fees from undertaking independent statistical review for Danone Nutricia Research, and a grant from the Food
Standards Agency, both outside of the submitted work.
TC has no known conflicts of interest. He was an investigator on a trial included in this review, but did not assess risk of bias for this trial.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Previous versions of this review used random-eIects models for meta-analyses, and the protocol for this review, which was shared with
the Cochrane Tobacco Addiction Group, stated that this was the preference of the review authors; however, during editing it was made
clear to the review authors that the policy of the Cochrane Tobacco Addiction Group is for fixed-eIect models to be used when assessing
pharmacotherapies, as it is not expected that relative eIects will diIer across populations and settings within the pregnant population.
We have therefore adopted the fixed-eIect approach for smoking abstinence outcomes. The safety outcome analyses remain as random-
eIects models.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Tobacco Use Cessation Devices;  Bupropion  [therapeutic use];  Nicotinic Agonists  [therapeutic use];  Pregnancy Complications  [*drug
therapy];  Pregnancy Outcome;  Randomized Controlled Trials as Topic;  Smoking Cessation  [*methods];  Varenicline  [therapeutic use]
MeSH check words
Female; Humans; Pregnancy
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